[COMPANY_001] Research and Development
LNP023 (Iptacopan) 
Clinical Trial Protocol CLNP023C12302
A randomized, multicenter, active-comparator controlled, 
open-label trial to evaluate efficacy and safety 
of oral, twice daily LNP023 
in adult patients with PNH and residual anemia, 
despi[INVESTIGATOR_554369]-C5 antibody
Document type: Amended Clinical Trial Protocol
EUDRACT number: 2019-004665-40
Version number: 02 (Clean)
Clinical Trial Phase: III
Release date: 23-Nov-2021
Property of [COMPANY_001] 
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 3.0 (31-Jan-2020)
[COMPANY_001] Confidential Page 2 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Table of contents
Table of contents..................................................................................................................[ADDRESS_728387] of abbreviations ............................................................................................................7
Glossary of terms...............................................................................................................10
Protocol summary..............................................................................................................16
1 Introduction........................................................................................................................19
1.1 Background ............................................................................................................19
1.2 Purpose...................................................................................................................21
2 Objectives and endpoints...................................................................................................22
2.1 Primary estimands..................................................................................................23
2.2 Secondary estimands..............................................................................................24
3 Study design.......................................................................................................................26
4 Rationale ............................................................................................................................29
4.1 Rationale for study design......................................................................................29
4.2 Rationale for dose/regimen and duration of treatment...........................................31
4.3 Rationale for choice of control drugs (comparator/placebo) or combination 
drugs.......................................................................................................................32
4.4 Purpose and timing of interim analyses/design adaptations ..................................33
4.5 Risks and benefits ..................................................................................................33
4.6 Rationale for Public Health Emergency mitigation procedures.............................36
5 Study Population................................................................................................................36
5.1 Inclusion criteria ....................................................................................................36
5.2 Exclusion criteria ...................................................................................................37
6 Treatment...........................................................................................................................39
6.1 Study treatment ......................................................................................................40
6.1.1 Investigational and control drugs ..........................................................40
6.1.2 Additional study treatments...................................................................41
6.1.3 Treatment arms/group ...........................................................................41
6.1.4 Treatment duration ................................................................................41
6.2 Other treatment(s) ..................................................................................................41
6.2.1 Concomitant therapy .............................................................................41
6.2.2 Prohibited medication............................................................................42

[COMPANY_001] Confidential Page 3 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
6.2.3 Rescue medication.................................................................................43
6.3 Participant numbering, treatment assignment, randomization...............................43
6.3.1 Participant numbering ...........................................................................43
6.3.2 Treatment assignment, randomization...................................................44
6.4 Treatment blinding.................................................................................................44
6.5 Dose escalation and dose modification..................................................................44
6.6 Additional treatment guidance...............................................................................45
6.6.1 Treatment compliance ...........................................................................45
6.6.2 Recommended treatment of adverse events ..........................................45
6.7 Preparation and dispensation .................................................................................46
6.7.1 Handling of study treatment and additional treatment ..........................47
6.7.2 Instruction for prescribing and taking study treatment..........................47
7 Informed consent procedures.............................................................................................48
8 Visit schedule and assessments..........................................................................................49
8.1 Screening................................................................................................................56
8.1.1 Information to be collected on screening failures .................................56
8.1.2 Hemoglobin assessments and transfusion during Screening.................56
8.1.3 Absolute Reticulocytes Count during Screening...................................57
8.2 Participant demographics/other baseline characteristics........................................57
8.3 Efficacy ..................................................................................................................57
8.3.1 Hemoglobin, reticulocytes, LDH and other PNH-related laboratory 
parameters..............................................................................................58
8.3.2 Red blood cell transfusion.....................................................................58
8.3.3 Breakthrough hemolysis........................................................................59
8.3.4 Patient Reported Outcomes (PRO) – FACIT-Fatigue...........................59
8.3.5 PNH-related signs & symptoms ............................................................60
8.3.6 Major Adverse Vascular Events (MAVEs)...........................................60
8.3.7 Appropriateness of efficacy assessments ..............................................61
8.4 Safety .....................................................................................................................62
8.4.1 Laboratory evaluations ..........................................................................62
8.4.2 Electrocardiogram (ECG)......................................................................63
8.4.3 Pregnancy and assessments of fertility..................................................64
8.4.4 Coagulation panel/thrombosis...............................................................64
8.4.5 Reproductive and thyroid hormones monitoring...................................64
8.4.6 Urine albumin creatinine ratio (UACR)................................................65
8.4.7 Appropriateness of safety measurements ..............................................65
[COMPANY_001] Confidential Page 4 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
8.5 Additional assessments ..........................................................................................65
8.5.1 Clinical Outcome Assessments (COAs)................................................65
8.5.2 Pharmacokinetics...................................................................................67
8.5.3 Biomarkers ............................................................................................68
8.6 Off-site research nursing (ORN) visits ..................................................................[ADDRESS_728388]-study treatment...........................................................75
10 Safety monitoring and reporting ........................................................................................75
10.1 Definition of adverse events and reporting requirements ......................................75
10.1.1 Adverse events.......................................................................................75
10.1.2 Serious adverse events...........................................................................77
10.1.3 SAE reporting........................................................................................78
10.1.4 Pregnancy reporting...............................................................................79
10.1.5 Reporting of study treatment errors including misuse/abuse ................79
10.2 Additional Safety Monitoring ................................................................................80
10.2.1 Liver safety monitoring .........................................................................80
10.2.2 Data Monitoring Committee..................................................................81
10.2.3 Steering Committee...............................................................................81
11 Data Collection and Database management ......................................................................81
11.1 Data collection .......................................................................................................81
11.2 Database management and quality control ............................................................82
11.3 Site monitoring.......................................................................................................82
12 Data analysis and statistical methods.................................................................................83
12.1 Analysis sets...........................................................................................................83
12.2 Participant demographics and other baseline characteristics.................................84
12.3 Treatments..............................................................................................................84
12.4 Analysis of the primary endpoint(s)/estimand(s)...................................................84
12.4.1 Definition of primary endpoint(s)/estimand(s)......................................84
12.4.2 Statistical model, hypothesis, and method of analysis ..........................85
12.4.3 Handling of remaining intercurrent events of primary estimand ..........87
12.4.4 Handling of missing values not related to intercurrent event................87
[COMPANY_001] Confidential Page 5 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
12.4.5 Sensitivity analyses for primary endpoint/estimand..............................87
12.4.6 Supplementary analysis.........................................................................87
12.4.7 Supportive analyses...............................................................................88
12.5 Analysis of secondary endpoints/estimands ..........................................................88
12.5.1 Safety endpoints ....................................................................................90
12.5.2 Pharmacokinetics...................................................................................92
12.5.3 Patient reported outcomes .....................................................................92
12.6 .........................................................................93
12.7 Interim analyses .....................................................................................................94
12.8 Sample size calculation..........................................................................................94
12.8.1 Primary endpoint(s)...............................................................................94
12.8.2 Secondary endpoint(s)...........................................................................95
13 Ethical considerations and administrative procedures.......................................................95
13.1 Regulatory and ethical compliance........................................................................95
13.2 Responsibilities of the investigator and IRB/IEC..................................................95
13.3 Publication of study protocol and results...............................................................95
13.4 Quality Control and Quality Assurance.................................................................96
14 Protocol adherence.............................................................................................................96
14.1 Protocol amendments.............................................................................................96
15 References..........................................................................................................................97
16 Appendices.......................................................................................................................100
16.1 Appendix 1: Clinically notable laboratory values................................................100
16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements.........................................................................................................101
16.3 Appendix 3: Full description of graphical procedure used for testing of 
primary and secondary endpoints ........................................................................104

[COMPANY_001] Confidential Page 6 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
List of tables
Table 2-1 Objectives and related endpoints for the Randomized Treatment 
period.....................................................................................................22
Table 2-2 Objectives and related endpoints for the Treatment Extension 
period.....................................................................................................23
Table 6-1 Investigational and control drug............................................................40
Table 6-2 LNP023 dose and treatment schedule ...................................................47
Table 8-1 Assessment schedule - Randomized treatment period ..........................51
Table 8-2 Assessment Schedule - Treatment Extension period.............................54
Table 8-3 Breakthrough definition.........................................................................59
Table 8-4 Assessments and specifications.............................................................62
Table 8-5 Laboratory tests .....................................................................................63
Table 8-6 PK blood log: participants Randomized to LNP023 arm......................67
Table 8-7 PK blood log: participants Randomized to comparator arm .................[ADDRESS_728389] of the assessments to be performed during by [CONTACT_78150]-site research 
nursing visit ...........................................................................................71
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse..........................................................................................[ADDRESS_728390] of figures
Figure 3-1 Study design ..........................................................................................26
Figure 12-1 Graphical display of multiple testing procedure ...................................86
[COMPANY_001] Confidential Page 7 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
List of abbreviations
AE Adverse Event
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
aPTT Activated Partial Thromboplastin Time
AST Aspartate Aminotransferase
AUC Area Under the Curve
b.i.d. bis in die/twice a day
BMF Bone Marrow Failure
BTH Breakthrough hemolysis
BUN Blood Urea Nitrogen
CDS Core Data Sheet
CK Creatinine Kinase
CMO&PS Chief Medical Office and Patient Safety
CO Country Organization
COA Clinical Outcome Assessment
COVID-19 Coronavirus Disease 2019
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CSR Clinical Study Report
CV Coefficient of Variation
DBP Diastolic Blood Pressure
DMC Data Monitoring Committee
ECG Electrocardiogram
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
EORTC QLQ-
C30European Organization For The Research And Treatment Of Cancer Quality Of Life 
Questionnaire
EVH Extravascular Hemolysis
EOS End of Study
ePRO Electronic Patient Reported Outcome
EQ-5D-5L EuroQol - 5 Dimensions- 5 Level
eSAE Electronic Serious Adverse Event
ESA Erythropoiesis Stimulating Agent
eSource Electronic Source
FAS Full Analysis Set
FDA Food and Drug Administration
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GCS Global Clinical Supply
GGT Gamma-glutamyl transferase
h Hour
HIF-PHI Hypoxia-inducible factor prolyl hydroxylase inhibitors
HIV Human immunodeficiency virus
HRQoL Health-Related Quality of Life
[COMPANY_001] Confidential Page 8 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
i.v. Intravenous
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization of Technical Requirements for Pharmaceuticals for 
Human Use
IEC Independent Ethics Committee
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology
IVH Intravascular Hemolysis
LDH Lactate dehydrogenase
LFT Liver Function Test 
LLOQ Lower Limit Of Quantification
MAVE Major Adverse Vascular Event
MedDRA Medical Dictionary for Regulatory Activities 
mg Milligram(s)
mL Milliliter(s)
OATP Organic Anion-Transporting Polypeptide 
ORN Off-site Research Nursing
PGIS Patient Global Impression of Severity
P-gp Permeability glycoprotein
p.o. oral(ly)
PD Pharmacodynamic(s)
PK Pharmacokinetic(s)
PNH Paroxysmal nocturnal hemoglobinuria
[COMPANY_003] Premature Participant Discontinuation
PRO Patient Reported Outcomes
PT prothrombin time
QD Once a day
QMS Quality Management System
QTcF QT interval corrected by [CONTACT_6550]’s formula
RAP The Report and Analysis Plan 
RBC Red Blood Cell(s)
RDC Remote Data Capture
REB Research Ethics Board
REP Roll-over Extension Program
RU Resource Utilization
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SBP Systolic Blood Pressure
sCR serum creatinine
SD Standard Deviation
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TBL Total Bilirubin
[COMPANY_001] Confidential Page 9 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
TD Study Treatment Discontinuation
ULN Upper Limit of Normal
WBC White Blood Cell(s)
WHO World Health Organization 
WoC Withdrawal of Consent
[COMPANY_001] Confidential Page 10 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Glossary of terms
Additional 
treatmentMedicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product or control drug (e.g. any background 
therapy)
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study participant 
Cohort A specific group of participants fulfilling certain criteria and generally treated at the same 
time
Control drug A study drug (active or placebo) used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data using 
data collection systems, such as Web-based applications, interactive voice response 
systems and clinical laboratory interfaces. EDC includes the use of Electronic Case 
Report Forms (eCRFs) which are used to capture data transcribed from paper source 
forms used at the point of care
End of the clinical 
trialThe end of the clinical trial is defined as EOS of the last participant as defined by [CONTACT_554393]/time of participant entry into the study at which informed consent must be obtained 
Estimand A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_301987]. It summarizes at a population-level what the outcomes would be in the 
same patients under different treatment conditions being compared. Attributes of an 
estimand include the population, variable (or endpoint) and treatment of interest, as well 
as the specification of how the remaining intercurrent events are addressed and a 
population-level summary for the variable.
Healthy volunteer A person with no known significant health problems who volunteers to be a study 
participant 
Intercurrent events Events occurring after treatment initiation that affect either the interpretation or the 
existence of the measurements associated with the clinical question of interest.
Investigational 
drug/ treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Mis-randomized 
participantsMis-randomized participants are those who were not qualified for randomization and who 
did not take study treatment, but have been inadvertently randomized into the study 
Other treatment Treatment that may be needed/allowed during the conduct of the study (i.e. concomitant 
or rescue therapy)
Part A sub-division of a study used to evaluate specific objectives or contain different 
populations. For example, one study could contain a single dose part and a multiple 
dose part, or a part in participants with established disease and in those with newly-
diagnosed disease
Participant A trial participant (can be a healthy volunteer or a patient)
Participant number A unique number assigned to each participant upon signing the informed consent. This 
number is the definitive, unique identifier for the participant and should be used to 
identify the participant throughout the study for all data collected, sample labels, etc.
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow-up) which are 
described in the Protocol. Periods define the study phases and will be used in clinical 
trial database setup and eventually in analysis
[COMPANY_001] Confidential Page 11 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Personal data Participant information collected by [CONTACT_554394]. This data includes participant identifier 
information, study information and biological samples.
Premature 
participant 
withdrawalPoint/time when the participant exits from the study prior to the planned completion of all 
study drug administration and/or assessments; at this time all study drug administration 
is discontinued and no further assessments are planned
Randomization 
numberA unique identifier assigned to each randomized participant
Screen Failure A participant who did not meet one or more criteria that were required for participation in 
the study
Source 
Data/DocumentSource data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a spreadsheet or even hard-
coded data, such as paper or eSource
Start of the clinical 
trialThe start of the clinical trial is defined as the signature [CONTACT_6671] [CONTACT_554395]; includes investigational drug(s), control(s) or 
background therapy
Study treatment 
discontinuationWhen the participant permanently stops taking any of the study drug(s) prior to the 
defined study treatment completion date (if any) for any reason; may or may not also be 
the point/time of study discontinuation 
Treatment 
arm/group A treatment arm/group defines the dose and regimen or the combination, and may 
consist of [ADDRESS_728391], which 
might or might not be the same as the study treatment.
Variable (or 
endpoint)The variable (or endpoint) to be obtained for each participant that is required to address 
the clinical question. The specification of the variable might include whether the 
participant experiences an intercurrent event.
Withdrawal of 
study consent 
(WoC)Withdrawal of consent from the study occurs only when a participant does not want to 
participate in the study any longer and does not allow any further collection of personal 
data
[COMPANY_001] Confidential Page 16 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Protocol summary
Protocol number CLNP023C12302
Full Title A randomized, multicenter, active-comparator controlled, open label trial to evaluate 
efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual 
anemia, despi[INVESTIGATOR_554369]-C5 antibody
Brief Title Study of efficacy and safety of twice daily oral LNP023 in adult PNH patients with residual 
anemia despi[INVESTIGATOR_6698]-C5 antibody treatment
Sponsor and 
Clinical Phase[COMPANY_001]
Phase III
Investigation 
typeDrug
Study type Interventional
Purpose and 
rationaleThe purpose of this Phase 3 study is to determine whether LNP023 is efficacious and 
safe for the treatment in PNH through demonstration of superiority of LNP023 compared 
to anti-C5 antibody treatment in adult PNH patients presenting with residual anemia 
despi[INVESTIGATOR_40792]-C5 antibody therapy
Primary 
Objective(s)The primary objectives are to:
Demonstrate superiority of LNP023 compared to anti-C5 antibody treatment in the 
proportion of participants achieving a sustained increase in hemoglobin levels from 
baseline of ≥ 2 g/dL in the absence of red blood cell transfusions.
Demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, in the 
proportion of participants achieving sustained hemoglobin levels ≥ 12 g/dL in the 
absence of red blood cell transfusions.
The primary clinical questions of interest are: What is the treatment effect of LNP023 at a 
dose of 200 mg b.i.d. versus anti-C5 antibody treatment in PNH patients with residual 
anemia, regardless of discontinuation of study medication and occurrence of 
breakthrough hemolysis or Major Adverse Vascular Events (MAVEs), on the odds of 
being a responder, with the endpoints defined as a composite of 
An increase in Hb levels from baseline ≥ 2 g/dL
Hb levels ≥ 12 g/dL
both assessed between Day 126 and Day 168 and of not requiring RBC transfusions 
between Day 14 and Day 168.
Secondary 
ObjectivesTo demonstrate superiority of LNP023, compared to anti-C5 antibody treatment in 
transfusion avoidance as the proportion of participants who remain free from 
transfusions by [CONTACT_554396] 14 and Day 168
To demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, in 
average change in hemoglobin by [CONTACT_554397] (g/dL) as mean of visits between Day 126 and Day 168
To demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, in 
improving fatigue, using the FACIT-Fatigue questionnaire by [CONTACT_554398]-Fatigue scores as mean of visits between Day 126 and Day 
168
To demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, in 
average change in reticulocyte counts by [CONTACT_554399] (109/L) as mean of visits between Day 126 and Day 168
To demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, 
in average percent change in LDH by [CONTACT_554400] (U/L) as mean of visits between Day 126 and Day 168
To demonstrate superiority of LNP023, compared to anti-C5 antibody treatment, in 
the rate of breakthrough hemolysis (BTH) of participants with breakthrough 
hemolysis reported between Day 1 and Day 168
[COMPANY_001] Confidential Page 17 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
To assess rates of MAVEs (incl. thrombosis) of LNP023, compared to anti-C5 
antibody treatment occurring between Day 1 and Day 168
The assessment of safety and tolerability of LNP023 compared to anti-C5 antibody 
treatment 
Study design This study is a multi-center, randomized, open-label, active comparator-controlled, 
parallel group study, which is comprised of a screening period, a 24-week, active 
controlled, parallel group treatment period and a 24-week LNP023 treatment extension 
period.
Study population Approximately ninety one (91) patients diagnosed with PNH, who are treated with a 
stable regimen of anti-C5 antibody (Standard of Care (SoC); either eculizumab or 
ravulizumab) for at least 6 months prior to Randomization, but still presenting with 
residual anemia (i.e., Hb < 10 g/dL) will be enrolled.
Key Inclusion 
criteriaMale and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by 
[CONTACT_5019]-sensitivity flow cytometry with RBCs and WBCs granulocyte/monocyte clone 
size ≥ 10%
Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumab 
or ravulizumab) for at least 6 months prior to randomization
Mean hemoglobin level <10 g/dL 
Over a minimum of 4 months before screening visit 
Confirmed by [CONTACT_554401]
Vaccination against Neisseria meningitidis infection is required prior to the start of 
treatment. If the patient has not been previously vaccinated, or if a booster is 
required, vaccine should be given according to local regulations, at least [ADDRESS_728392] dosing.
If not received previously, vaccination against Streptococcus pneumoniae and 
Haemophilus influenzae infections should be given, if available and according to 
local regulations. The vaccines should be given at least [ADDRESS_728393] dosing.
Key Exclusion 
criteriaParticipants on a stable eculizumab dose but with a dosing interval of 11 days or less 
or participants on stable ravulizumab dose but with a dosing interval of less than 8 
weeks.
Known or suspected hereditary complement deficiency at screening
History of hematopoietic stem cell transplantation
Patients with laboratory evidence of bone marrow failure (reticulocytes <100x109/L; 
platelets <30x109/L; neutrophils <500x106/L).
Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days 
prior to study drug administration
A history of recurrent invasive infections caused by [CONTACT_22711], e.g. 
meningococcus or pneumococcus. 
Major concurrent comorbidities including but not limited to severe kidney disease 
(e.g., eGFR < 30 mL/min/1.73 m2,dialysis) , advanced cardiac disease (e.g., NYHA 
class IV), severe pulmonary disease (e.g., severe pulmonary) hypertension (WHO 
class IV), or hepatic disease (e.g., active hepatitis) that in the opi[INVESTIGATOR_554370]'s participation in the study.
Study treatment LNP023
Anti-C5 antibodies (either eculizumab or ravulizumab)
Treatment of 
interestThe randomized treatment (the investigational treatment LNP023 200 mg b.i.d. or stable 
regimen of anti-C5 antibody therapy (SoC)) regardless of whether patient discontinues 
treatment (treatment policy). 
Efficacy 
assessmentsHemoglobin, reticulocytes, LDH and other PNH-related laboratory parameters
Red blood cell transfusions
Breakthrough hemolysis
[COMPANY_001] Confidential Page 18 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Patient Reported Outcomes (PRO)–FACIT-Fatigue
Major Adverse Vascular Events (MAVEs) incl. thrombosis
Key safety 
assessmentsLaboratory evaluations in blood and urine
Adverse event monitoring
ECG
Coagulation panel/thrombosis
Reproductive and thyroid hormones monitoring
Other 
assessments An assessment of patient-reported outcomes is planned in this trial using European 
Organization For The Research And Treatment Of Cancer Quality Of Life Questionnaire 
(EORTC QLQ-C30), EuroQol - 5 Dimensions- 5 Level (EQ-5D-5L), and Patient Global 
Impression of Severity of fatigue (PGIS). Exploration of the meaningfulness of the change 
demonstrated in patient report outcomes will be performed with an optional Patient 
Interview.
Data analysis All efficacy analyses will use the full analysis set (FAS) that includes all patients 
randomized into the study.
Primary efficacy estimands represented by [CONTACT_106342]:
Proportions of participants achieving a sustained increase in hemoglobin levels from 
baseline ≥ 2 g/dL between Day 126 and Day 168 in the absence of transfusions 
between Day 14 and Day 168 
Proportions of participants achieving sustained hemoglobin levels ≥ 12 g/dL between 
Day [ADDRESS_728394] derived from a 
conditional logistic model accounting for the stratification factors used at randomization 
and with adjustment for baseline hemoglobin levels and sex, used in the analysis of the 
two endpoints. Besides the odds ratio a marginal logistic model adjusting for stratification 
factors and covariates will be used to compare the proportions of both treatments using 
standardization.
Secondary efficacy estimands represented by [CONTACT_106342]:
Proportions of participants who are transfusion free by [CONTACT_554402] 14 and Day 168
Differences in average change from baseline in hemoglobin levels between Day 126 
and Day 168 estimated under the hypothetical condition of being free from transfusion 
between Day 14 and Day 168
Differences in average score changes from baseline evaluated between Day 126 and 
Day 168 of FACIT-Fatigue
Differences in average changes from baseline in reticulocyte counts evaluated 
between Day 126 and Day 168
Differences in average percent change from baseline in LDH evaluated between Day 
126 and Day 168
Rates of breakthrough hemolysis between Day 1 and Day 168 
Rates of MAVEs between Day 1 and Day 168
Following successful rejection of the hypotheses associated with the primary estimands, 
the secondary estimand hypotheses will be tested applying weighted Simes’ tests with 
pre-defined weights allocated to the different levels of secondary hypotheses. The testing 
procedure applies alpha propagation rules according to the principles of graphical 
procedures for multiplicity adjustment. The estimands of interest as well as methods for 
obtaining comparisons are described in detail in the corresponding sections.
Key words LNP023, eculizumab, ravulizumab, anti-C5, PNH, LDH, hemoglobin, anemia
[COMPANY_001] Confidential Page 19 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
1 Introduction
1.1 Background
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hemolytic disorder 
characterized by [CONTACT_30937]-mediated intravascular hemolysis, bone marrow failure (BMF) 
and severe thrombophilia (Risitano 2012). It begins with the clonal expansion of a 
hematopoietic stem cell that has acquired a somatic mutation in the phosphatidylinositol N-
acetylglucosaminyltransferase subunit A (PI[CONTACT_149099]) gene (Brodsky 2014). Consequently, PNH 
blood cells lack the glycophosphatidylinositol (GPI) anchor protein and are deficient in the 
membrane-bound complement inhibitory proteins CD55 and CD59. As a result, PNH type red 
blood cells (RBCs) are attacked by [CONTACT_554403].
The clinical spectrum of PNH varies and signs and symptoms include anemia, thrombosis, 
smooth muscle dystonia, fatigue, hemoglobinuria, chronic kidney disease and pulmonary 
hypertension. The clinical presentation is driven by [CONTACT_554404]55 and CD59 deficient PNH type RBCs culminating with hemolysis and the release of free 
hemoglobin, and platelet activation (Hill et al 2013). Hemolysis results in release of 
intracellular hemoglobin and lactate hydrogenase (LDH) into the circulation. Irreversible 
binding to and inactivation of nitric oxide (NO) by [CONTACT_554405], result in abdominal pain, dysphagia, 
erectile dysfunction, platelet activation and a prothrombotic status (Brodsky 2014, 
Hill et al 2013). Thromboembolism is the leading cause of morbidity and mortality in patients 
with PNH and can occur at any site; although venous is more common (80–85%), it can also be 
arterial (15–20%) (Hillmen et al 2007).
Eculizumab and Ravulizumab (engineered from eculizumab with prolonged dosing interval) 
are approved anti-C5 antibody therapi[INVESTIGATOR_554371] (SoC) where available. The introduction of eculizumab has significantly reduced the 
thromboembolic risk of PNH patients improving morbidity and mortality and largely improved 
the quality of life (QoL) of PNH patients.
Although the anti-C5 antibody treatment is generally effective in treating intravascular 
hemolysis (IVH), there remains a high unmet medical need for PNH. Different authors reported 
heterogeneous hematological response with eculizumab and a substantial proportion of patients 
not achieving normal or near normal hemoglobin levels (McKinley et al 2017, 
DeZern et al 2013, Hill et al 2010, Risitano et al 2009). In the study of Risitano and colleagues, 
approximately one third of patients treated with eculizumab achieved normal or near normal 
hemoglobin levels (hemoglobin ≥ 11 g/dL) without requiring red blood cell transfusions 
(Risitano et al 2009). 
Until recently, well defined response categories to complement inhibitor therapy have not been 
established. A classification of hematological response with anti-complement agents has been 
proposed by [CONTACT_554406] (SAA) Working Party of the European group for Bone 
Marrow Transplantation (EBMT) (Risitano et al 2019). The classification has been applied to 
a large cohort of [ADDRESS_728395] been reported 
(Debureaux P-E 2019) after the first six months of treatment with eculizumab (n=80). 
[COMPANY_001] Confidential Page 24 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
medication and occurrence of breakthrough hemolysis or MAVEs, on the odds of being a 
responder, with the endpoint defined as a composite of Hb levels ≥ 12 g/dL assessed between 
Day 126 and Day 168 without requiring RBC transfusions between Day 14 and Day 168?
The justification of this primary estimand is that it will capture the hematological benefit of the 
study drug as a normalization of hemoglobin levels that is achieved free from RBC transfusions 
(which are regarded as treatment failure).
Further details can be found in Section 12.
The two primary estimands share the following attributes:
Population: Patients with PNH who are on a stable regimen of SoC (anti-C5 antibody 
treatment) and have residual anemia (Hb < 10 g/dL). Further details about the population 
are provided in Section 5.
Treatment of interest: the randomized treatment (the investigational treatment LNP023 200 
mg b.i.d. or anti- C5 therapy (SoC)) regardless of whether patient discontinues treatment 
(treatment policy). Further details about the investigational treatment and control treatment 
are provided in Section 6.
Intercurrent events: Transfusions will be considered treatment failures whereas 
discontinuations of study medication for any reason, breakthrough hemolysis events, and 
MAVEs will be handled with a treatment policy strategy.
The summary measure: the probability of being a responder on each treatment in the studied 
patient population tested as an odds ratio.
However, the estimands differ in the definition of the associated endpoints as the proportion of 
responders where the responder definitions are as follows:
Responder defined as a participant having Hb ≥ 2 g/dL increase from baseline between Day 
126 and Day 168 and who has not received a RBC transfusion between Day 14 and Day 
168 of the randomized treatment period.
Responder defined as a participant having Hb ≥ 12 g/dL between Day [ADDRESS_728396], summary measure as the primary estimand and the analysis 
and details are stated in Section 12.4.6.
2.2 Secondary estimands
The population associated with the secondary estimands is the same as for the primary 
estimands. For these secondary estimands we consider the same intercurrent events as for the 
[COMPANY_001] Confidential Page 25 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
primary estimands. The proposed approach in the case of transfusion handling will be described 
in the estimand definition, while discontinuations of study medication, breakthrough hemolysis 
events, and MAVEs will be handled with a treatment policy strategy. 
The secondary estimands are defined by [CONTACT_554407]:
Proportions of participants not receiving any transfusions between Day 14 and Day 168 
(Transfusion Avoidance). The summary measure is the same as for the two primary 
endpoints.
Difference in achieved hemoglobin changes from baseline between Day 126 and Day 168 
where transfusions occurring between Day 14 and Day 168 are treated within a hypothetical 
strategy (as if the participants had not received any transfusions). The summary measure is 
the comparison of the mean changes from baseline in hemoglobin levels assessed between 
Day 126 and Day 168.
Difference in change from baseline in scores of fatigue using the FACIT Fatigue 
questionnaire between Day 126 and Day 168, where the strategy applied to transfusions is 
treatment policy. The summary measure is the comparison of mean changes from baseline 
in FACIT fatigue scores assessed between Day 126 and Day 168.
Difference in change from baseline in reticulocytes counts between Day 126 and Day 168 
where the strategy applied to transfusions is treatment policy. The summary measure is the 
comparison of the mean changes from baseline in reticulocyte counts assessed between Day 
126 and Day 168.
Difference in percent change from baseline in LDH between Day 126 and Day 168 where 
the strategy applied to transfusions is treatment policy. The summary measure is the 
comparison of the log transformed LDH ratio to baseline assessed between Day 126 and 
Day 168.
Rates of breakthrough hemolysis occurring between Day 1 and Day 168. The summary 
measure is a rate difference.
Rates of MAVE between Day [ADDRESS_728397]. The planned analyses in 
Section 12 could be supplemented by [CONTACT_554408].
[COMPANY_001] Confidential Page 26 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
3 Study design
This study is a multi-center, randomized, open-label, active comparator-controlled, parallel 
group study, which is comprised of three periods (see Figure 3-1):
A screening period lasting up to 8 weeks (unless there is a need to extend it for vaccinations 
required for inclusion, vaccinations should be started at the earliest possible to avoid 
extension of the screening period)
A 24-week randomized, open-label, active controlled, parallel group treatment period for 
the primary efficacy and safety analyses
A 24-week open-label, LNP023 treatment extension period
The study will enroll PNH patients with residual anemia, defined as hemoglobin < 10 g/dL, 
despi[INVESTIGATOR_554372]-C5 antibody treatment (eculizumab or ravulizumab) in the last 6 
months before randomization, with approximately 40% of participants having received at least 
[ADDRESS_728398] 
participant has completed the Day 168 visit in the study or EOS (End of Study) for participants 
who discontinue from the study prior to the treatment extension period. The final database lock 
will take place when the last participant has completed the last visit (Day 336 or EOS) in the 
treatment extension period.
Screening
Screening period starts at the time of ICF signing and lasts until the day preceding Day 1 of the 
randomized treatment period.

[COMPANY_001] Confidential Page 27 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Participants will be asked to review and sign the informed consent form prior to proceeding for 
the screening assessments. After signing ICF, during this visit, inclusion and exclusion criteria 
will be assessed to verify participants' eligibility for enrollment into the study. This will be 
followed by [CONTACT_99816]'s assessments as outlined in Table 8-1, as applicable.
By [CONTACT_12568], the participants will provide access to the following records: hemoglobin 
levels reported at least during the last 4 months; the numbers of transfusions and unit numbers 
of packed-RBC received in the last 12 months prior to Screening; Major Adverse Vascular 
Events (MAVEs) reported prior to screening (History of MAVE); and the anti-C5 antibody 
regimen they have followed for the last 6 months up to randomization (History of anti-C5 
antibody treatment).
Vaccinations should be completed as per Inclusion criteria defined in Section 5.1. Vaccines 
should cover as many serotypes as possible (including meningococcal serotypes A, C, Y, W-135 
and B). To minimise participant burden, the use of multivalent vaccines is recommended as 
locally available and per local guidelines and regulations (e.g. quadrivalent vaccine for 
N. meningitidis which covers serotypes A, C, Y and W-135 and Pneumovax-23 which covers 
23 S. pneumoniae serotypes). For the vaccination type and booster requirements use local 
guidelines, and locally available vaccines (and refer to the package insert of those, or local 
guidelines). The screening period may be extended to allow vaccination procedures to be 
completed, in case of multiple vaccination needs and local/country requirements. This is 
applicable for vaccinations only, while all the other screening assessments must be performed 
as indicated in the Assessment Schedule Table 8-1.Vaccinations should be started at the earliest 
possible to avoid extension of screening period. There is a possibility that administration of a 
vaccine to a patient with PNH could stimulate complement production and worsen hemolysis. 
In order to mitigate this possibility, it may be preferred to start treatment with iptacopan within 
[ADDRESS_728399] two different samples 
collected during the screening period and tested by [CONTACT_554409] 
<10 g/dL, prior to Randomization. In case the participant has received a RBC transfusion 
following the initial sample collection, the patient is eligible based on the initial central 
hemoglobin value if < 10 g/dL.
The absolute reticulocytes count will be measured at Screening to determine eligibility with 
regards to exclusion criterion # 6. Due to the kinetics of maturation of reticulocytes into mature 
red blood cells and turnaround time from reticulocytes sample collection and analysis by [CONTACT_21921], local reticulocytes testing can be performed at the same time as the central testing 
during the Screening period. In the event that the absolute reticulocytes count as assessed by 
[CONTACT_554410] 
(absolute reticulocytes < 100x109/L) and only in this scenario, the results from the local lab 
testing can be used to determine participant’s eligibility. The results of the local laboratory 
values (including reference ranges) should be included in the eCRF to document eligibility. 
If eligibility criteria are not met due to any assessment, the participant should be considered as 
having failed the screening and does not proceed to randomization. The participant can be re-
screened as described in detail in Section 8.1 .
[COMPANY_001] Confidential Page 28 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Investigators should refer to the locally approved label of eculizumab and ravulizumab for 
recommendation of use and in accordance with local practice.
Randomization
The randomization will be stratified into four strata (defined by [CONTACT_554411]). Participants who meet the eligibility criteria at screening will be stratified 
based on the type of prior anti-C5 antibody treatment (eculizumab or ravulizumab) and based 
on the transfusion history as reported during the last 6 months prior to randomization (i.e. 
transfusion received/not received). It is assumed that approximately 40% of randomized 
participants having received at least one packed red blood cell (pRBC) transfusion in the 6 
months prior to randomization.
Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 
monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 
antibody treatment (approximately 35 participants continuing with the same regimen during the 
randomized treatment period as they were on prior to randomization), respectively.
Randomized Treatment period
Treatment will start on the first day of dosing (Day 1) and continue for [ADDRESS_728400] 
one (eculizumab) or two (ravulizumab) weeks of prior anti-C5 and LNP023 treatment.
Please refer to Section 8.3.[ADDRESS_728401] the investigator or local physician immediately in case of 
suspi[INVESTIGATOR_554373]. 
Upon completion of the Week 24 visit, participants may enter the treatment extension period, 
as described below.
[COMPANY_001] Confidential Page 29 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Treatment Extension period 
The participants randomized to the active comparator arm will be offered to switch to 
LNP023 on Day 168 (Week 24 visit) and enter the treatment extension period, after receiving 
a last dose of anti-C5 (eculizumab or ravulizumab) antibody treatment. For participants in the 
comparator arm not agreeing to switch treatment, Week 24 will be the End of Study visit for 
the trial and there will be no participation in the treatment extension period. For participants 
agreeing to switch to oral LNP023, the Extension treatment will start on the day after 
completion of the Week 24 visit.
After switching to LNP023, the participants in the comparator arm will follow study visits and 
assessments according to schedule described in Table 8-2. 
The participants in the LNP023 arm, who benefit from treatment and are taking LNP023 at 
Week 24 visit (i.e. did not permanently discontinue study medication), will be offered to 
continue the oral treatment during the treatment extension period, with study visits and 
assessments according to schedule detailed in Table 8-2. For participants not agreeing to 
continue in the treatment extension period after completing Day [ADDRESS_728402] 24 weeks. After completion of the treatment extension 
period, the participant will be able to join the Roll-over extension program (REP), which will 
provide access to LNP023 and enable long-term safety monitoring. For participants not 
agreeing to continue in the Roll-over extension program (REP) after completing Day 336 visit, 
End of Study will be after completing recommended procedures defined in Section 9.1.1
4 Rationale
4.1 Rationale for study design
CLNP023C12302 is designed as a multicenter, open-label, randomized, active-comparator 
controlled, parallel group study for demonstration of superiority of LNP023 at a dose of 200 
mg b.i.d. orally compared to intravenous anti-C5 antibody treatment on hematological response 
parameters and patient reported outcome measures for fatigue, in patients with PNH that present 
with residual anemia despi[INVESTIGATOR_12847] a stable regimen of anti-C5 antibody treatment 
(SoC).
The study population consists of PNH patients with residual anemia defined by a mean 
hemoglobin value below 10 g/dL (with approx. 40% requiring RBC transfusions in the past 6 
months) for inclusion in the study despi[INVESTIGATOR_554374], i.e., anti-C5 antibody treatment 
of eculizumab or ravulizumab. This represents a population for which there remains a need 
for improved efficacy. In a retrospective analysis of a cohort of 93 PNH patients classifying 
hematological response to eculizumab treatment, it has been shown that after 6 months of 
eculizumab treatment (n=80), 54% of participants have a hemoglobin value of less than 10 
g/dL with or without the need of RBC transfusions during that period 
[COMPANY_001] Confidential Page 30 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
(Debureaux P-E et al 2019). The 54% included patients meeting the criteria for partial, minor 
or no hematological response according to the novel classification of hematological response 
to eculizumab (Risitano et al 2019).
Approximately 40% of randomized participants are required to have received at least one 
packed red blood cell (pRBC) transfusion in the [ADDRESS_728403], transfusion independence has been 
achieved in 51% of eculizumab treated patients after 26 weeks of treatment (Hillmen et al 2006) 
and 51% of eculizumab treated patients after 52 weeks of treatment (Brodsky et al 2008), 
respectively. More recently, transfusion avoidance rates after 26 weeks of treatment were 
reported with 66.1% and 73.6% in eculizumab and ravulizumab treated patients respectively 
(Lee et al 2019).
The randomization will be stratified based on prior anti-C5 antibody treatment (eculizumab or 
ravulizumab) and by [CONTACT_554412] (any transfusion 
administered in the 6 months prior to Randomization), both factors that could impact 
hematological response.
A multicenter setting has been chosen to ensure adequate recruitment and enrollment into the 
study in this rare indication. A randomized, active-comparator controlled study design for the 
main treatment period has been selected to appropriately assess LNP023’s efficacy and safety 
and demonstration of superior efficacy compared to anti-C5 antibody treatment in support of 
its registration.
The randomization ratio of 8:5 has been chosen in order to maximize the number of PNH 
participants who are treated with LNP023 and increase the efficacy and safety data collected 
with LNP023 in this rare population. The initiation of LNP023 treatment has an overlap of 1 
(eculizumab) or 2 (ravulizumab) weeks with prior anti-C5 antibody treatment to ensure that 
participants are not at risk of breakthrough hemolysis while minimizing potential carry-over 
effects of prior anti-C5 antibody treatment. 
An open-label design is appropriate for the selected primary and majority of secondary efficacy 
endpoints, which are objectively measured (i.e. hematological response parameters, 
hemoglobin, LDH, reticulocytes, transfusion avoidance and breakthrough hemolysis). Protocol-
specific guidelines (see Section 8.3.2) were defined to reduce potential bias in the determination 
of endpoints including transfusion avoidance.
The randomized treatment period of [ADDRESS_728404] of 
LNP023 on the primary and secondary efficacy endpoints as well as on safety and tolerability, 
similar to the treatment duration of the Phase 3 studies with eculizumab and ravulizumab
(Lee et al 2019; Kulasekararaj et al 2019). Because the comparator arm includes both 
eculizumab and ravulizumab, the potential carry-over effects of the longer acting ravulizumab 
were taken into account by [CONTACT_554413] 24 weeks randomized treatment period instead of 
e.g. 16 weeks reported in the PEGASUS trial with only eculizumab as comparator 
(Study Registry ID: [REMOVED]).
Two hematological responder endpoints will be used for the primary efficacy analysis of the 
randomized treatment period:
[COMPANY_001] Confidential Page 31 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
1. A hematological responder defined as a participant achieving an increase from baseline in 
hemoglobin levels ≥ 2 g/dL (assessed during the last 6 weeks of the 24 weeks randomized 
treatment period) without the need of RBC transfusions from Day 14 to Day 168. This 
endpoint comprises 1) a sustained improvement in hemoglobin of at least 2 g/dL from 
baseline and 2) transfusion independence for treatment success, both clinically important 
treatment goals in PNH. The choice of an increase of at least 2 g/dL in hemoglobin in the 
absence of transfusions is because it approximates an increase that can be achieved with 
the administration of a RBC transfusion (1-2 units), thereby [CONTACT_554414].
2.2. A hematological responder defined as a participant achieving hemoglobin levels ≥ 12 
g/dL (assessed during the last 6 weeks of the 24 weeks randomized treatment period) 
without the need of RBC transfusions from Day 14 to Day 168. This endpoint comprises 
1) hemoglobin normalization and 2) transfusion independence for treatment success, also 
both clinically important treatment goals in PNH.
An interval of six weeks at the end of the randomized treatment period with four assessments, 
and [ADDRESS_728405] six weeks of the 24 weeks randomized treatment period are used 
for determining hematological response (≥ 2 g/dL hemoglobin increase from baseline; 
hemoglobin ≥12 g/dL) to ensure that it reflects the actual treatment effect of either LNP023 or 
anti-C5 antibody treatment.
Considering that some patients may present with very low hemoglobin levels (e.g. < 7 g/dL), 
and thereby [CONTACT_554415] a red blood cell transfusion during the first two weeks of the randomized 
treatment period, transfusions administered during these first 2 weeks will not be considered 
for the transfusion avoidance definition.
Secondary efficacy endpoints include transfusion avoidance and breakthrough hemolysis, a 
patient reported outcome measure for fatigue (FACIT-Fatigue) as well as changes in 
reticulocytes and LDH and MAVEs. They were selected to supplement the primary efficacy 
endpoints and are clinically meaningful endpoints for hemolytic PNH.
A treatment extension period of 24 weeks will provide further safety and efficacy data on 
LNP023 in PNH patients.
4.2 Rationale for dose/regimen and duration of treatment
The dose of 200 mg LNP023 b.i.d. as continuous treatment has been selected for this study 
primarily based on the available efficacy and safety data obtained at the time of interim analyses 
from the two ongoing Phase 2 PNH studies and is supported by [CONTACT_554416].
In the CLNP023X2201 study in patients with active hemolysis despi[INVESTIGATOR_554375], LNP023 at a dose of 200 mg b.i.d. was administered to 10 PNH participants 
(cohort 1) and at a dose of 50 mg b.i.d. to 6 PNH participants (cohort 2). An interim analysis 
(IA) was conducted after 10 participants (cohort 1) completed at least 13 weeks of treatment 
with LNP023 200 mg b.i.d. add-on treatment to eculizumab.
In the CLNP023X2204 study in PNH patients not treated with eculizumab/complement 
inhibition, participants were randomized to LNP023 monotherapy in two sequences with forced 
titration after 4 weeks from LNP023 25 mg b.i.d. to 100 mg b.i.d (sequence 1) or LNP023 50 
[COMPANY_001] Confidential Page 32 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
mg b.i.d. to 200 mg b.i.d. (sequence 2). An IA was conducted after the first 8 patients were 
randomized and 7 patients completed Week 8 visit assessments.
The dose of 200 mg b.i.d. is expected to provide optimal efficacy required for PNH as 
monotherapy with an adequate safety profile based on the following key findings of the two 
interim analyses:
Participants treated with LNP023 200 mg b.i.d. (as add-on to eculizumab) had clinical 
benefits not achieved with eculizumab that included control of IVH demonstrated by [CONTACT_554417], control of EVH demonstrated by [CONTACT_554418], reticulocytes and increase 
in haptoglobin resulting in normalization of hemoglobin in the majority of patients in the 
absence of red blood cell transfusions. The hematological response participants achieved 
with LNP023 200 mg b.i.d. add-on therapy was maintained with LNP023 monotherapy 
during the extension period (at the time of the IA) when eculizumab treatment was 
discontinued in 5/[ADDRESS_728406] and profound 
and sustained reduction of Fragment Bb demonstrating target engagement.
Participants receiving LNP023 monotherapy showed that LNP023 at dose levels ≥ 25 mg 
b.i.d. had LDH reduction of more than 60% from baseline in all participants and early 
transfusion-free hemoglobin increase in the majority of participants. Other hemolysis 
relevant laboratory values indicated that LNP023 administered as monotherapy controls 
both, intra (LDH reduction) and extravascular hemolysis (decrease of reticulocytes and 
bilirubin, increase in haptoglobin).
Preliminary information from cohort [ADDRESS_728407] participants requiring up-titration to the dose of 200 mg b.i.d.
LNP023 at a dose of 200 mg b.i.d. was safe and well tolerated by [CONTACT_554419], as well as at the same dose in patients with IgA nephropathy (study CLNP023X2203) 
and C3 glomerulopathy (CLNP023X2202), supporting its use in this study.
The exposure-response model developed with data from the First In Human (FIH) study with 
LNP023 in healthy volunteers predicts that a dose of about 200 mg b.i.d. would be needed to 
achieve > 90% inhibition of the alternative pathway (Wieslab assay) in > 70% of subjects. Given 
the risk of hemolysis and breakthroughs in cases of insufficient inhibition of complement 
activity, full inhibition is desired and modelling results provide additional support for the choice 
of the dose of 200 mg b.i.d. for PNH. For further details, please refer to the LNP023 Investigator 
Brochure.
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
For this study, an active control has been selected due to the life-threatening nature of the 
disease. To date the only approved, targeted therapi[INVESTIGATOR_554376] 33 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
ravulizumab, two anti-C5 monoclonal antibodies inhibiting cleavage of C5 to C5a and C5b. 
The study allows inclusion of patients treated with either eculizumab or ravulizumab, at stable 
regimen. For eculizumab (administered as intravenous infusion every 2 weeks), the 
maintenance dose is a fixed dose, whereas for ravulizumab (administered as intravenous 
infusion every 8 weeks), the maintenance dose is based on body weight.
Eculizumab is the current Standard of Care (SoC) for PNH patients with hemolysis and the 
clinical program with eculizumab demonstrated prevention of intravascular hemolysis, 
hemoglobin stabilization, and reduction/avoidance of red blood cell transfusions 
(Brodsky et al 2008, Hillmen et al 2006) as well as reduction of the thromboembolic risk 
(Hillmen et al 2007). Its approval in 2007 and subsequent introduction has significantly changed 
the disease course where available and improved morbidity and mortality. 
Ravulizumab (engineered from eculizumab with prolonged dosing interval) approved in [ADDRESS_728408] eculizumab as SoC, given the added 
convenience of an 8-week administration regimen. Data from two clinical trials demonstrated 
non-inferiority of ravulizumab to eculizumab (Lee et al 2019; Kulasekararaj et al 2019) 
providing justification for the choice of ravulizumab and eculizumab in the control arm.
While anti-C5 agents are effective in inhibiting intravascular hemolysis in most patients, only 
a small proportion of patients achieve normal to near normal hemoglobin values and there 
remains an unmet medical need to inhibit extravascular hemolysis not prevented by [CONTACT_14181]-C5 
antibody treatment (please refer to Section 1.1). Participants are expected to continue with their 
stable anti-C5 antibody treatment regimen (which they were on during the six months prior to 
randomization) throughout the randomized treatment period. Any changes in dose and/or 
infusion interval should be avoided.
4.4 Purpose and timing of interim analyses/design adaptations
Periodic monitoring of safety data and emerging risk/benefit will be carried out by a Data 
Monitoring Committee (DMC). To this end, interim reports with analysis results using 
treatment group labels available only to the DMC will be generated by [CONTACT_554420]. The randomization list will be made available in 
a firewalled area for the purpose of generating interim analysis reports.
4.[ADDRESS_728409] relevant risks are described below and a complete 
description of preclinical safety findings is available in the LNP023 Investigator Brochure. The 
safety results from the CLNP023X2201 study (PNH patients treated with eculizumab) as well 
as CLNP023X2204 study (anti-C5 treatment-naïve PNH patients) are summarized in the 
Investigator Brochure. LNP023 at a dose of 200 mg b.i.d. has been generally safe and well 
tolerated in these studies. 
Appropriate eligibility criteria, as well as study specific stoppi[INVESTIGATOR_554377]. 
Recommended guidelines for monitoring of and management of infections are provided in 
[COMPANY_001] Confidential Page 34 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Section 6.6.2. The risk to participants in this trial will be minimized by [CONTACT_554421], close clinical monitoring with appropriate risk mitigation strategies, and 
periodic review of the safety data by [CONTACT_3153]. This study does not involve any 
risks regarding study procedures (e.g. no invasive research procedures). One theoretical risk 
which is specific to PNH patients is the risk of hemolysis following discontinuation of treatment 
with a complement inhibitor. This is managed by [CONTACT_554422] 9.1.1.
LNP023 did not show any mutagenic, teratogenic or genotoxic potential in completed standard 
battery of genotoxicity testing. In addition, LNP023 was tested in embryo-fetal development 
studies in rats and rabbits and no LNP023-related adverse fetal findings were detected in any 
of the studies. However, LNP023 has not been used in pregnant women, therefore, women of 
child-bearing potential must be informed that taking the study treatment may involve unknown 
risks to the fetus if pregnancy were to occur during the study, and agree that in order to 
participate in the study they must adhere to the contraception requirements outlined in the 
exclusion criteria. If there is any question that the participant will not reliably comply, they 
should not be entered or continue in the study.
Based on the preliminary results from the CLNP023X2201 study as well as CLNP023X2204 
study (Section 4.2 for details), patients randomized to LNP023 may have clinical benefits over 
and above the SoC including:
Increase of hemoglobin to normal/near normal values in the absence of red blood cell 
transfusions
Control of extravascular hemolysis
Reduction of LDH
It is expected that the improved hematological response upon LNP023 treatment will translate 
into improved quality of life, most importantly an improvement in fatigue. More details about 
the preliminary results of the Phase [ADDRESS_728410] (CP) with C5-blockers like eculizumab. Serum bactericidal activity studies of serum 
from vaccinated patients against meningococci showed that C5 inhibitors block killing of 
meningococci, whereas AP inhibitors have less inhibitory effect on meningococcal killing 
(Konar and Granoff 2017). Vaccination is therefore predicted to be an effective mitigation 
strategy to reduce the risk for individuals treated with LNP023. Participants will be vaccinated 
against meningococcal, pneumococcal and H. influenzae  infections according to local 
guidelines and availabilities, since these are all encapsulated bacteria.
[COMPANY_001] Confidential Page 35 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Participants will also be closely monitored for signs and symptoms of infection (listed on a 
“Participant Safety Card” for participant awareness) and will be instructed to contact [CONTACT_92685] a local physician if they experience these symptoms. The investigator will 
employ clinical judgement to determine an appropriate course of treatment. Antibiotic treatment 
should be started immediately for infections caused by [CONTACT_65125], with action taken 
with study medication considered on a case-by-case basis. Recommended guidelines for 
monitoring and management of infections are provided in Section 6.6.2. For 
immunocompromised participants with a higher risk of infections, precautionary actions (e.g. 
prophylactic antibiotics) should be considered by [CONTACT_093].
Other safety risks are based on preclinical data, with no relevant findings in clinical studies 
performed to date. There are potential risks of testicular effects, bone marrow toxicity with 
severe anemia, aorta mineralization and increase in heart weight and thyroid changes. The 
preclinical findings are described in more detail in the Investigator Brochure.
In the LNP023 clinical studies, there have been no serious testicular adverse events or changes 
from baseline in reproductive hormones reported to date. Since the testicular effects seen in 
preclinical studies have been shown to be mild and reversible with no notable effect on sperm 
or hormone levels in dogs, and a reasonable safety margin when comparing unbound 
concentrations achieved in the dog at the lowest dose where an effect was seen (LOAEL) and 
the concentrations achieved in man at the [ADDRESS_728411] dose level for which the exposure to LNP023 for unbound levels was more than 80-fold 
greater than that observed with the 200 mg b.i.d. dose of LNP023 in the clinic (see Investigator’s 
Brochure). There have been no adverse events or blood chemistry values reported which are 
relevant to the bone marrow toxicity seen in the dog. Hematological parameters will continue 
to be monitored in Phase 3 studies.
Increases in heart weight and mineralization of the aortic wall were observed at dose levels 
≥30 mg/kg/day in very young dogs (4 weeks old at the start of treatment, equivalent to 6-12 
months of age in humans) after [ADDRESS_728412] been observed; however, they were minimal and reversible. 
There have been no clinically relevant thyroid adverse events or changes in thyroid hormone 
levels in clinical trials to date. Thyroid hormone levels will continue to be monitored in 
Phase 3 studies.
In addition, safety results from completed studies in 108 healthy volunteers exposed to LNP023 
(84 to single doses and 24 to multiple doses over two weeks) indicated that treatment was well 
tolerated. Overall, no deaths or SAEs were reported, no imbalances from placebo in rates of 
[COMPANY_001] Confidential Page 36 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
AEs and no AEs which led to study drug discontinuation. Similarly, the two Phase 2 studies in 
patients with PNH (29 patients exposed to LNP023), studies carried out in complement-driven 
renal disease (IgA nephropathy study, in which 87 patients were exposed to LNP023 and C3G 
studies, in which 27 patients were exposed to LNP023) confirmed that the safety profile was 
favorable and supported continuation of development.
In summary, the benefit risk relationship for LNP023 is positive supporting the start of this 
study.
4.6 Rationale for Public Health Emergency mitigation procedures
During a Public Health emergency as declared by [CONTACT_6586] i.e. pandemic, 
epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety and trial integrity 
are listed in relevant sections. Notification of the Public health emergency should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by 
[CONTACT_6588].
5 Study Population
Patients diagnosed with PNH, who are treated with a stable regimen of anti-C5 monoclonal 
antibody treatment (Standard of Care; either eculizumab or ravulizumab) for at least 6 months 
prior to randomization, but still presenting with residual anemia (i.e., Hb < 10 g/dL) will be 
enrolled. Approximately 40% of participants having received at least [ADDRESS_728413] meet all of the following criteria:
1. Written informed consent must be obtained before any assessment is performed.
2.Male and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by 
[CONTACT_5019]-sensitivity flow cytometry (Borowitz et al 2010) with RBCs and with WBCs 
granulocyte/monocyte clone size ≥ 10%.
3. Stable regimen (dose and intervals) of anti-C5 antibody treatment (either eculizumab or 
ravulizumab) for at least 6 months prior to Randomization.
4. Mean hemoglobin level <10 g/dL:
Documented by [CONTACT_2669] 2 measurements over a minimum of 4 months (medical 
history data) before Screening visit
And confirmed by [CONTACT_554423]:
By [CONTACT_554424] (mean <10 g/dL), two up to eight weeks 
apart, for patients not receiving a pRBC transfusion during Screening.
By [CONTACT_554425] (<10 g/dL) carried at the first Screening visit 
for patients receiving a pRBC transfusion after which he/she will be eligible.
[COMPANY_001] Confidential Page 37 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
5. Vaccination against Neisseria meningitidis infection is required prior to the start of 
treatment. If the patient has not been previously vaccinated, or if a booster is required, 
vaccine should be given according to local regulations, at least [ADDRESS_728414] be initiated.
7. Able to communicate well with the investigator, to understand and comply with the 
requirements of the study.
5.2 Exclusion criteria
Participants meeting any  of the following criteria are not eligible for inclusion in this study.
1. Participation in any other investigational drug trial or use of other investigational drugs at 
the time of enrollment, or within 5 elimination half-lives of enrollment, or within 30 days 
of enrollment whichever is longer; or longer if required by [CONTACT_427].
2. Participants on a stable eculizumab dose but with a dosing interval of 11 days or less or 
participants on stable ravulizumab dose but with a dosing interval of less than 8 weeks.
3. History of hypersensitivity to any of the study drugs or its excipi[INVESTIGATOR_201014].
4. Known or suspected hereditary complement deficiency at screening.
5. History of hematopoietic stem cell transplantation.
6. Patients with laboratory evidence of bone marrow failure (reticulocytes <100x109/L, (or 
<100x106/mL); platelets <30x109/L, (or <30x 106/mL); neutrophils <500x106/L, (or 
<500x103/mL).
7. Active systemic bacterial, viral (incl. COVID-19) or fungal infection within 14 days prior 
to study drug administration.
8.Presence of fever ≥ 38 °C (100.4 °F) within 7 days prior to study drug administration.
9. Human immunodeficiency virus (HIV) infection (known history of HIV or test positive for 
HIV antibody at Screening).
10. A history of recurrent invasive infections caused by [CONTACT_22711], e.g. 
meningococcus or pneumococcus. 
11. Major concurrent comorbidities including but not limited to severe kidney disease 
(e.g., eGFR < 30 mL/min/1.73 m2, dialysis), advanced cardiac disease (e.g., NYHA class 
IV), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or 
hepatic disease (e.g., active hepatitis) that in the opi[INVESTIGATOR_554378]'s participation in the study.
12. Liver disease, such as active HBV or HCV infection defined as HBsAg positive or HCV 
RNA positive, or liver injury as indicated by: [CONTACT_554426]:
[COMPANY_001] Confidential Page 38 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Any single parameter of ALT, GGT, alkaline phosphatase must not exceed 3×upper 
limit of normal (ULN)
13. Unstable medical condition including, but not limited to, myocardial ischemia, active 
gastrointestinal bleeding, coexisting chronic anemia unrelated to PNH, or unstable 
thrombotic event not amenable to active treatment as judged by [CONTACT_554427].
14. History of malignancy of any organ system (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless 
of whether there is evidence of local recurrence or metastases.
15. Any medical condition deemed likely to interfere with the patient’s participation in the 
study. 
16. Concomitant use of any of the following medications is prohibited if not on a stable 
regimen for the time period indicated below prior to Screening and those listed in 
Section 6.2.2:
Erythropoiesis-stimulating agents (ESAs) or immunosuppressants for at least 8 weeks
Systemic corticosteroids given for hematological conditions (less than 1 mg/kg) for at 
least 4 weeks
Vitamin K antagonists (e.g., warfarin) with a stable international normalized ratio (INR) 
for at least 4 weeks
Low-molecular-weight heparin, and the direct oral anticoagulants (DOACs) 
rivaroxaban, api[INVESTIGATOR_119896], for at least 4 weeks
Iron supplements, vitamin B12, or folic acid for at least 4 weeks
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) such as roxadustat 
for at least 8 weeks 
17. Female patients who are pregnant or breastfeeding, or intending to conceive during the 
course of the study.
18. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using effective methods of contraception during dosing 
of study treatment and for 1 week after stoppi[INVESTIGATOR_554379]023, 5 months after stoppi[INVESTIGATOR_554380] 8 months after stoppi[INVESTIGATOR_554381]. Effective contraception methods 
include:
Total abstinence (when this is in line with the preferred and usual lifestyle of the 
participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before 
taking study treatment. In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by [CONTACT_104]
Male sterilization (at least 6 m prior to screening). For female participants on the study, 
the vasectomized male partner should be the sole partner for that participant
[COMPANY_001] Confidential Page 39 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps). For [LOCATION_006]: with spermicidal foam/gel/film/cream/vaginal 
suppository
Use of oral (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy 
(failure rate <1%), for example hormone vaginal ring or transdermal hormone 
contraception or placement of an intrauterine device (IUD) or intrauterine system 
(IUS)
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_728415] had 12 months of natural (spontaneous) 
amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor 
symptoms). Women are considered not of child bearing potential if they are post-
menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), 
total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of 
oophorectomy alone, only when the reproductive status of the woman has been confirmed 
by [CONTACT_6592].
If local regulations deviate from the contraception methods listed above to prevent 
pregnancy, local regulations apply and will be described in the ICF. 
19. Ongoing drug or alcohol abuse that could interfere with patient's participation in the trial
6 Treatment
Participants will be randomized in an 8:5 ratio to either LNP023 monotherapy given orally b.i.d. 
(where the anti-C5 antibody treatment will be stopped – See below for timing), or intravenous 
anti C5 antibody treatment (continuing with the same dose as that received prior to 
randomization).
LNP023 first administration (Day 1 visit)
The timing of the first LNP023 administration will provide a seamless switch from prior anti-
C5 antibody treatment to LNP023, allowing for some overlap of exposure to anti-C5 antibody 
treatment when starting the oral agent while limiting the potential risk of breakthrough 
hemolysis, as the LNP023 exposure builds-up.
First LNP023 dose administration of participants on prior eculizumab regimen must occur 
at days [ADDRESS_728416] infusion
First LNP023 dose administration for participants on prior ravulizumab regimen must occur 
at days [ADDRESS_728417] infusion
Participants will then continue taking 200 mg LNP023 b.i.d. monotherapy.
[COMPANY_001] Confidential Page 40 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Anti-C5 first administration in the study (Day 1 visit)
Participants assigned to the comparator arm will continue receiving the anti-C5 infusion as per 
their stable regimen. It will be ensured that the participants and their physicians have relevant 
educational material and eculizumab or ravulizumab specific Participant Safety cards. However, 
the day of the next administration of anti-C5 for the ‘study start’ should coincide with ‘Day 1’ 
study day. The investigator is encouraged to ‘count back’ from the schedule date for the planned 
infusion.
Treatment Extension period: LNP023 administration for comparator group 
At Week [ADDRESS_728418] LNP023 dose administration the morning after the visit (Day 169).
With participants starting in the treatment extension period taking LNP023 starting on Day 169, 
the visit schedule will be harmonized, with the exception of Day 175, where only participants 
formerly assigned to the comparator arm will return for PK and safety assessments.
6.1 Study treatment
6.1.1 Investigational and control drugs
In this study, the ''study treatment'' includes the investigational drug, LNP023, and the active 
comparators of anti-C5 antibodies (either eculizumab or ravulizumab).
Table 6-1 Investigational and control drug
Investigational/ 
ComparatorPharmaceutical dosage 
formRoute of 
administrationSupply type
LNP023, [ADDRESS_728419] gelatin capsule Oral use Open label, patient 
specific kits
Eculizumab, 300 mg/30mL Concentrate solution for 
infusionIntravenous infusion Open label, vial
Ravulizumab, 300 mg/30 
mLConcentrate solution for 
infusionIntravenous infusion Open label, vial
Ravulizumab, 300 mg/3 
mL**Concentrate solution for 
infusionIntravenous infusion Open label, vial
Ravulizumab, 1100 mg/11 
mL**Concentrate solution for 
infusionIntravenous infusion Open label, vial
LNP023, 10* mg Hard gelatin capsule Oral use Open label, patient 
specific kits
*used only during tapering down of LNP023 dose – see Section 9.1.1 for details
**If available commercially and provided by [CONTACT_554428], LNP023 as 10 mg and 200 mg capsules, will be prepared by [CONTACT_554429]-label participant packs.
Eculizumab and ravulizumab will be provided locally by [CONTACT_3452], subsidiary or designee 
as commercially available or by [CONTACT_5343], in each participating country according to local 
practices and local regulations.
[COMPANY_001] Confidential Page 41 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
6.1.2 Additional study treatments
No other treatment beyond investigational drug and control drug are included in this trial.
6.1.3 Treatment arms/group
Participants will be randomized to one of the two treatment arms in an 8:5 ratio to LNP023 
monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 
antibody treatment (approximately 35 participants continuing with the same stable regimen as 
that prior to randomization), respectively.
6.1.4 Treatment duration
The duration of the randomized Treatment period is 24 weeks. If a participant’s treatment with 
LNP023 is discontinued and participant is switched back to the prior anti-C5 antibody treatment, 
every effort will be made to continue with the study assessments up to the Week [ADDRESS_728420] up to 24 weeks, where participants randomized to 
LNP023 arm during the randomized treatment period will be offered to continue with LNP023 
treatment, and participants randomized to anti-C5 arm will be offered to switch to LNP023 
monotherapy. If a participant permanently discontinues LNP023 during the treatment extension 
period, the Investigator should follow the recommended procedures for discontinuation (see 
Section 9.1.1). If possible, participant should continue with the study assessments up to the 
Week [ADDRESS_728421]-trial access 
(PTA) by [CONTACT_554430]-over extension program (REP) to allow participants access to 
LNP023 and to enable long-term safety monitoring. PTA will be provided until one of the 
following is met: participant no longer derives clinical benefit, investigator discontinues 
treatment, launch or reimbursement (where applicable), treatment fails to achieve registration 
in the trial participant’s country, or the clinical program is discontinued for any other reason.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy) 
administered after the participant was enrolled into the study must be recorded on the 
appropriate Case Report Forms. Please refer to Section 8.3.[ADDRESS_728422] all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a participant or allowing a new medication to be started. If the participant is 
already enrolled, contact [CONTACT_6596].
[COMPANY_001] Confidential Page 42 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
[IP_ADDRESS] Permitted concomitant therapy requiring caution and/or action
Erythropoiesis-stimulating agents (ESAs) and hypoxia inducible factors prolyl hydroxylase 
inhibitors (HIF-PHIs) are allowed to be used if on stable dose at least [ADDRESS_728423] the dose and/or discontinue dosing of ESAs 
and/or HIF-PHIs based on participant’s hemoglobin level as per local guidelines and practice. 
As a general guide, it is recommended to reduce the ESA and/or HIF-PHIs dose by 50% if 
hemoglobin is ≥ 12 g/dL and/or to stop ESA and/or HIF-PHIs dosing if hemoglobin is 
≥ 13 g/dL.  Use particular caution in participants with coexisting cardiovascular disease, stroke 
and chronic kidney disease. 
LNP023 has been shown to have a weak inhibition potential for the liver uptake transporter 
OATP1B1. Calculation revealed that the exposure (AUC) of respective sensitive substrates may 
be increased by <1.[ADDRESS_728424] on the exposure of respective co-
medications is small and may not be clinically relevant it is recommended to combine LNP023 
with sensitive OATP1B1 substrates or those having a narrow therapeutic index with caution or 
apply a staggered dosing (see below). A list of OATP1B1 substrates to be used with caution 
will be provided to the investigators.
LNP023 has also been shown to inhibit the efflux-transporter P-glycoprotein (P-gp) on the 
intestinal level but not the liver. Therefore, the direct oral anti-coagulation drugs api[INVESTIGATOR_3822], 
rivaroxaban and edoxaban which are P-gp substrates should be used with caution. For edoxaban 
a staggered dosing (see below) is recommended, in particular for participants with impaired 
kidney function.
For narrow therapeutic index (NTI) immunosuppressants (e.g. cyclosporine, sirolimus, 
tacrolimus on a stable dose) which are substrates for the efflux transporter P-gp with no 
alternative treatment available a staggered dosing approach is recommended. This can be 
accomplished by [CONTACT_554431]-medication >3hrs following oral 
administration of LNP023. Alternatively, compounds with a short Tmax of around < 2 hours 
(i.e., fast absorption) can be given >1hr prior to LNP023. The staggered dosing will avoid 
increases in systemic exposure of co-administered drugs due to P-gp inhibition by [CONTACT_554432]023 at 
the intestinal level. For participants receiving immunosuppressants (stable dose) and if their 
exposure is no longer monitored, it is advisable to resume therapeutic drug monitoring after 
start of treatment with LNP023 (single assessment).
6.2.2 Prohibited medication
Use of the treatments listed below are not allowed during LNP023 administration.
Live vaccines are prohibited for the entire study treatment duration
Preclinical studies have shown that systemic disposition of LNP023 is primarily mediated 
by [CONTACT_554433], predominantly by [CONTACT_097]2C8 and to a smaller extent by [CONTACT_554434]. In addition, some contribution from direct renal (approximately 20%) and 
direct biliary excretion (around 5 to 10%) is anticipated. LNP023 is also a substrate for the 
organic anion-transporting polypeptide (OATP) hepatic uptake transporter (see above). To 
ensure participant safety, co-medications that inhibit multiple disposition mechanisms of 
[COMPANY_001] Confidential Page 43 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
LNP023 (e.g. Gemfibrozil) are prohibited. The same applies to strong CYP2C8 inhibitors 
(main clearance pathway) such as clopi[INVESTIGATOR_7745].
Gemfibrozil (a potent inhibitor of metabolizing enzymes CYP2C8, UGT1A and liver 
uptake transporter OATP1B1) must be interrupted at least [ADDRESS_728425] 
LNP023 dose until end of LNP023 treatment (and replaced with another appropriate 
medication used for that indication)
Strong inhibitors of CYP2C8 such as clopi[INVESTIGATOR_554382] [ADDRESS_728426] 
LNP023 dose until end of LNP023 treatment (and replaced with another appropriate 
medication used for that indication)
Medications that are either “sensitive substrates” for the efflux transporter P-gp or have a 
narrow therapeutic index (NTI) and are substrates for P-gp should not be administered with 
LNP023 (interrupted [ADDRESS_728427] LNP023 dose). Typi[INVESTIGATOR_554383], 
quinidine, paclitaxel, fentanyl and phenytoin. However, if no alternative treatment is 
available, a staggered dosing approach is recommended (refer to Section [IP_ADDRESS]). The 
anti-coagulation drug dabigatran which is also a P-gp substrate should not be used in 
combination with LNP023 and a staggered dosing is also not recommended.
Concomitant medication listed under exclusion criterion 16 is prohibited, if not on a stable 
regimen prior to Screening, for the time periods indicated. 
6.2.3 Rescue medication
Rescue medication is allowed to treat serious complications such as thrombosis with anti-
thrombotic treatment and management of this complication as per local guidelines and practice. 
For significant breakthrough hemolysis requiring rescue medication in the opi[INVESTIGATOR_1070], rescue medication is allowed and should be managed as per local guidelines and 
practice.
6.3 Participant numbering, treatment assignment, randomization
6.3.1 Participant numbering
Each participant is identified in the study by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant 
throughout his/her participation in the trial. A new Participant No. will be assigned at every 
subsequent enrollment if the participant is re-screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential 
participant number suffixed to it, so that each participant’s participation is numbered uniquely 
across the entire database. Upon signing the informed consent form, the participant is assigned 
to the next sequential Participant No. available.
A new ICF will need to be signed if the investigator chooses to re-screen the participant after a 
participant has screen failed, and the participant will be assigned a new Participant No.
[COMPANY_001] Confidential Page 44 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
6.3.2 Treatment assignment, randomization
During screening and after hemoglobin eligibility is confirmed, all eligible participants will be 
randomized via Interactive Response Technology (IRT) to one of the treatment arms. The 
investigator or his/her delegate will contact [CONTACT_554435]/exclusion criteria. The IRT will assign a randomization number to the 
participant, which will be used to link the participant to a treatment arm and will specify a 
unique medication number for the first package of study treatment (for LNP023, and when 
applicable for anti-C5) to be dispensed to the participant.
Randomization should occur as closely as possible to the planned Day 1 (see Section 6) while 
taking into consideration availability of assigned treatment arm on site.
The randomization numbers will be generated ensuring that treatment assignment is unbiased 
and concealed from participants and investigator staff as is described in the following: A 
participant randomization list will be produced by [CONTACT_6609] a validated system 
that automates the random assignment of participant numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by [CONTACT_6610] (GCS) using a validated system that automates the random 
assignment of medication numbers to packs containing the study treatment.
Randomization will be stratified by [CONTACT_554436]-C5 antibody treatment (eculizumab or 
ravulizumab) and based on transfusion history as reported during the last 6 months prior to 
randomization (i.e. transfusion received / not received).
The randomization scheme for participants will be reviewed and approved by a member of the 
Randomization Office.
6.[ADDRESS_728428] will be released only to a firewalled area to those 
designated to access it to serve the purposes of creating reports for the DMC or the PK analysis.
6.5 Dose escalation and dose modification
LNP023 will be administered at 200 mg b.i.d. and anti-C5 antibody treatment will be 
administered at the stable regimen participants were on in the prior 6 months before 
randomization for the duration of the study. There are no dose adjustments planned for LNP023 
or anti-C5 antibody treatment.
[COMPANY_001] Confidential Page 45 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
6.[ADDRESS_728429] the investigator if he/she is unable for any reason to take the study 
treatment as prescribed and appropriate actions will be taken.
Compliance for LNP023 will be assessed by [CONTACT_1755]/or study personnel using 
capsule counts and information provided by [CONTACT_2299]. This information should be 
captured in the source document at each visit.
Participants on LNP023 will be given the opportunity to use a generic reminder 
application (app) that will synchronize with the participant mobile phone calendar to remind 
participants to take their medication. The participants may choose to report compliance to the 
study site staff through the app. The use of this application and the compliance reporting feature 
are entirely voluntary and not mandated for use.
For the comparator arm, study treatment is administered intravenously under the supervision 
of the Investigator or designee, thereby [CONTACT_554437].
All study treatments dispensed and returned must be recorded in the Drug Accountability Log.
6.6.2 Recommended treatment of adverse events
Infections
The participants and treating staff need to be instructed to be vigilant for any clinical signs of 
bacterial infections (e.g., malaise, chills, fever, nausea, photophobia, generalized muscle and 
joint pain) and to measure the body temperature at minimum at the times of symptoms of 
presumed infection. Participants will be instructed to contact [CONTACT_554438][INVESTIGATOR_554384] (> 38.3°C by [CONTACT_554439]) for a ‘phone directed’ triage.
In case of a suspected bacterial infection, participants should be immediately considered for 
emergency evaluation and empi[INVESTIGATOR_554385].
In case of any (bacterial and non-bacterial incl. COVID-19) severe infection, interruption of 
LNP023 dosing  could be considered, on a case-by-case basis. However, every effort should be 
taken to keep the participant on study treatment unless the risk outweighs the benefit in the 
opi[INVESTIGATOR_871]. 
If LNP023 treatment is to be permanently discontinued, please refer to Section 9.1.1 for the 
appropriate actions. 
If the participant is in the anti-C5 antibody treatment arm at the time of diagnosis of a serious 
bacterial infection, they should be treated immediately with appropriate antibiotics and any 
[COMPANY_001] Confidential Page 46 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
guidance in the local label for the anti-C5 inhibitor should be followed.
Medication used to treat adverse events (AEs) must be recorded on the appropriate CRF.
LNP023 Participant Safety Card
All participants will be provided with a Participant Safety Card. Participants will be instructed 
to be vigilant for any clinical sign or symptom of serious bacterial infection and to contact [CONTACT_554440][INVESTIGATOR_184010], in which case 
antibiotic treatment should be started as soon as possible.
Comparator Participant Safety Card
All participants randomized to continue on eculizumab or ravulizumab will be provided with 
the specific relevant Participant Safety card if they do not already have one. Participants will 
be instructed to be vigilant for any clinical sign or symptom of meningococcal infection and to 
contact [CONTACT_554441][INVESTIGATOR_554386], in which case antibiotic treatment should be started as soon as possible.
6.7 Preparation and dispensation
Each study site will be supplied with study drug in packaging as described under investigational 
and control drugs section.
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that limits or prevents on-site study visits, 
delivery of IMP directly to a participant’s home may be permitted (if allowed by [CONTACT_554442]) in the event the Investigator 
has decided that an on-site visit by [CONTACT_348178], and that 
it is in the interest of the participant’s health to continue administration of the study treatment 
even without performing an on-site visit. 
The dispatch of IMP from the site to the participant’s home remains under the accountability of 
the Investigator. Each shipment/provisioning will be for a maximum of 1-month supply. In this 
case, regular phone calls or virtual contacts (as per scheduled visits or more frequently if needed) 
will occur between the site and the participant for instructional purposes, safety monitoring, 
drug accountability, investigation of any adverse events, ensuring participants continue to 
benefit from treatment and discussion of the participant´s health status until the participants can 
resume visits at the study site.
LNP023
A unique medication number is printed on the study medication label.
Investigator staff will identify the study medication kits to dispense to the participant by 
[CONTACT_105245](s). The study medication has a 2-part 
label (base plus tear-off label), immediately before dispensing the medication kit to the 
participant, site personnel will detach the outer part of the label from the packaging and affix it 
to the source document.
[COMPANY_001] Confidential Page 47 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Anti-C5 antibody treatment (eculizumab, ravulizumab)
Preparation and dispensation should follow the locally approved label and local practice. During 
the 24-week randomized Treatment Period, participants randomized to anti-C5 antibody 
treatment must continue with same dose and schedule as they were before entering the study.
6.7.1 Handling of study treatment and additional treatment
[IP_ADDRESS] Handling of study treatment
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study treatment must be stored according to the 
instructions specified on the labels (comparators) or in the Investigator’s Brochure (LNP023).
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001] CO Quality Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the study treatment but no information about 
the participant except for the medication number.
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log. Monitoring of drug accountability will be performed by 
[CONTACT_30798]. Participants will be 
asked to return all unused study treatment and packaging at the end of the study or at the time 
of discontinuation of study treatment.
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return all unused study treatment, packaging, drug labels, and a copy of the completed drug 
accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
6.7.2 Instruction for prescribing and taking study treatment
LNP023
Participants should take LNP023 at the dose of 200 mg twice per day (in the morning and in 
the evening) at approximately the same times each day and ideally with 12-hours interval 
between morning and evening dosing. On study visit days, the participants should not take that 
day's morning dose until instructed by [CONTACT_554443].
Table 6-2 LNP023 dose and treatment schedule
Dose level Posology LNP023 dose strength
200 mg b.i.d. 1 capsule twice daily 200 mg
Participants should take LNP023 irrespective of food intake. Each dose should be taken with a 
glass of water.
[COMPANY_001] Confidential Page 48 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Participants should be instructed to swallow capsules whole and not to chew or open them.
If vomiting occurs during the course of treatment, participants should not take the study 
treatment (LNP023) again before the next scheduled dose.
Participants should be instructed not to make up missed doses. A missed dose is defined as a 
case when the full dose is not taken within 4 hours after the approximate time of the usually 
daily dosing. That dose should be omitted and the participant should continue treatment with 
the next scheduled dose.
Anti-C5 antibody treatment (eculizumab, ravulizumab)
Preparation and dispensation should follow the locally approved label and local practice. 
Participants randomized to anti-C5 antibody treatment must continue with same dose and 
schedule as they were before entering the study. A specific eculizumab or ravulizumab 
Participant Safety card and relevant educational material will be provided to participants 
receiving anti-C5 therapy, and study investigator. 
All kits of study treatment will be recorded in the IRT system.
7 Informed consent procedures
Eligible participants may only be included in the study after providing (witnessed, where 
required by [CONTACT_6617]), IRB/IEC-approved informed consent.
If applicable, in cases where the participant’s representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant is capable of doing so, he/she must 
indicate agreement by [CONTACT_30803].
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the participant source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_37250]/IEC.
Information about common side effects already known about the investigational drug can be 
found in the Investigator's Brochure (IB) (and/or CDS for marketed drugs). This information 
will be included in the participant informed consent and should be discussed with the 
participant during the study as needed. Any new information regarding the safety profile of the 
investigational drug that is identified between IB updates will be communicated as appropriate, 
for example, via an investigator notification or an aggregate safety finding. New information 
might require an update to the informed consent and then must be discussed with the participant.
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], that may challenge the ability to obtain 
a standard written informed consent due to limits that prevent an on-site visit, Investigator may 
[COMPANY_001] Confidential Page 49 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
conduct the informed consent discussion remotely (e.g. telephone, videoconference) if 
allowable by a local Health Authority.
Guidance issued by [CONTACT_554444] (e.g. the presence of an impartial witness, sign/dating separate ICFs 
by [CONTACT_6622], etc.).
The following informed consents are included in this study:
Main study consent, which also includes:
An additional signature [CONTACT_554473]
A subsection that requires a separate signature [CONTACT_30833] ‘Optional Consent for 
Additional Research’ to allow future research on data/samples collected during this 
study
A subsection that requires a separate signature [CONTACT_30833] ‘Optional Consent for Patient 
Interview’
Informed Consent Optional for genetic research
Informed Consent Form for Optional Off-site Research Nursing (ORN) visits during a 
pandemic 
Informed Consent Form for Optional Off-site Research Nursing (ORN) visits for 
Week 2 (Day 14) and/or Week 6 (Day 42) visits or in special circumstances
As applicable, Pregnancy Outcomes Reporting Consent for female participants who took 
study treatment
Women of child-bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception requirements.
The study includes an optional DNA component which requires a separate signature [CONTACT_554474]. It is required as part of this protocol that the Investigator 
presents this option to the participants, as permitted by [CONTACT_37251]. The process 
for obtaining consent should be exactly the same as described above for the main informed 
consent.
Declining to participate in these optional assessments (DNA) will in no way affect the 
participant’s ability to participate in the main research study.
A copy of the approved version of all consent forms must be provided to [COMPANY_001] after IRB/IEC 
approval.
8 Visit schedule and assessments
The assessment schedule (Table 8-1  and Table 8-2 ) lists all of the assessments when they are 
performed. All data obtained from these assessments must be supported in the participant’s 
source documentation.
Unless specified (i.e. post dose PK samples), all assessments should be performed prior to dose 
administration the day of visits.
[COMPANY_001] Confidential Page 50 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean) Protocol No. CLNP023C12302
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
(Tables 8-1 and Table 8-2) or as close to the designated day/time as possible. Missed or 
rescheduled visits should not lead to automatic discontinuation.
At the investigator’s discretion, and based on benefit-risk considerations of the participant’s 
clinical condition, and the local availability of services, some qualifying participants may be 
offered the option to receive home nursing to perform Week-2 and /or Week-[ADDRESS_728430] 
provide (a separate) consent in the optional Off-site Research Nursing Informed Consent. The 
participants are under no obligation to participate in off-site visits, as they can decide to continue 
with on-site visits at the study site.
The off-site visits will comply with all assessments indicated in Table 8-[ADDRESS_728431]-party vendor centrally sourced by [CONTACT_554445]. The qualified nurses will be under the delegation of the 
investigator. The investigator will retain accountability for participant’s oversight and all 
medical decisions (i.e. protocol specified medical procedures, AE/SAE assessment and 
reporting, changes in medication, etc.).
Participants who discontinue LNP023 treatment during the randomized treatment period should 
continue in the study up to Week [ADDRESS_728432] should be reconciled, and the adverse 
event and concomitant medications recorded on the CRF.
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_554387], that limits or 
prevents on-site study visits, alternative methods of providing continuing care may be 
implemented. Phone calls, virtual contacts (e.g. tele consult) or visits by [CONTACT_554446]´s home depending on local regulations and capabilities, can replace on-site 
study visits, for the duration of the disruption or until it is safe for the participant to visit the site 
again. For more details refer to Section 8.6.
[COMPANY_001] Confidential Page 51 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Table 8-1 Assessment schedule - Randomized treatment period
Period Screening Randomized treatment period
Visit Name [CONTACT_554475] 1 Day 7 Day 14 Day 28 Day 42 Day 56 Day 84Day 
112Day 
126Day 
140Day 
154Day9 
168
Days -56 to -1 -56 to -1 17
±114
±128
±142
±356
±384
±3112
±3126
±3140
±3154
±3168
±3
Weeks -8 to -1 -8 to -1 1 1 2 4 6 8 12 16 18 20 22 24
Informed consent X X11
Entry criteria X X
Demography X
Medical history/current medical 
conditionsX
Vaccination history & Vaccination X
Alcohol and Smoking history X
Hepatitis B, C and HIV screen X
Physical examination S S S S
Blood pressure and pulse rate X X X X X X X X X X X X X
Body height X
Body weight X X X X X
Body temperature X X X X X X X X X X X X X
Pregnancy test1S S S S
Clinical Chemistry (full) X X X X X
Clinical Chemistry (abbreviated) X X X X X X X X
Hematology (full)2X X (Hb only) X X X X X X X X X X X X
Coagulation/Markers of 
thrombosisX X X X X X X X
Panel of hormones blood 
samplesXXX X X X X X
[COMPANY_001] Confidential Page 54 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Table 8-2 Assessment Schedule - Treatment Extension period
Period Treatment Extension Period
Visit Name[Day 175]
x-comparator only **Day 196 Day 224 Day 252 Day 280 Day 308 Day336/EOS3
Days 175 ± 1 196 ± 5 224 ± 5 252 ± 5 280 ± 5 308 ± 5 336 ± [ADDRESS_728433] S
Clinical Chemistry (full) X X
Clinical Chemistry (abbreviated) X X X X X
Hematology (full) X X X X X X X
Coagulation/markers of thrombosis X X X X X X
Panel of safety hormones blood samples X X X X
X X X X
X X X
Urinalysis (dipstick) X X X X X X X
Urine Albumin/Creatinine ratio X X
Breakthrough hemolysis X
X X X X X X X
RBC transfusion X
12-lead Electrocardiogram (ECG) X
Adverse Events X
Major Adverse Vascular Events X
Concomitant medications X
X

[COMPANY_001] Confidential Page 55 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Period Treatme
nt Extension Period
Visit Name[Day 17
5]
x-comparator only **Day 19
6 Day 22
4 Day 252 Day 280 Day 308 Day336/EOS3
Days 175 ± 1 196 ± 5 224 ± 5 252 ± 5 280 ± 5 308 ± 5 336 ± 5
Weeks 25 28 32 36 40 44 48
Surgical and medical procedures X
Patient reported outcomes X X X X X X
IRT X X X X X X X
LNP023 Dispensing X X X X X
Study Drug Administration2 b.i.d. from Day 169
Disposition X
**Visit [Day 175] will be completed only by [CONTACT_554447]-24 visit and progressing into the treatment extension period
X = assessment to be recorded in the clinical database or received electronically from a vendor
S = assessment to be recorded in the source documentation only
2Study drug Administration: LNP023 to be administered b.i.d. daily to all participants in the treatment extension period.
3For participants not agreeing to continue in the roll-over extension program (REP) after completing Day 336 visit, End of Study will be after completing recommended 
procedures defined in Section 9.1.1. For participants prematurely discontinuing study treatment before Day 336 but remaining in the study for abbreviated visits, please 
refer to Section 9.1.1 for the close monitoring and additional assessments/visits to be performed in between abbreviated visits

[COMPANY_001] Confidential Page 56 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
8.1 Screening
Screening activities (Table 8-1) must be initiated only after the participant has signed the ICF.
Rescreening participants
It is permissible to re-screen a participant if the participant fails the first screening; however, 
each case must be discussed and agreed with [COMPANY_001] on a case-by-case basis. 
In the case where a safety laboratory assessment (this excludes Hemoglobin laboratory 
assessment) at screening is outside of the range specified in the entry criteria, the assessment 
may be repeated once prior to randomization. If the repeat value remains outside of the specified 
ranges, the participant must be excluded from the study.
8.1.1 Information to be collected on screening failures
Participants who sign an informed consent form and are subsequently found to be ineligible 
will be considered a screen failure. The reason for screen failure should be entered on the 
applicable Case Report Form. The demographic information, informed consent, and 
Inclusion/Exclusion eCRFs must also be completed for screen failure participants. No other 
data will be entered into the clinical database for participants who are screen failures, unless the 
participant experienced a serious adverse event during the screening phase (Section 10.1.3 ). 
Adverse events that are not SAEs will be followed by [CONTACT_554448].
Participants who sign an informed consent and are considered eligible but fail to be started on 
treatment for any reason will be considered an early terminator. The reason for early termination 
should be captured on the appropriate disposition Case Report Form.
8.1.[ADDRESS_728434] 4 months prior to screening. The 
mean/average of at least [ADDRESS_728435] be below 10 g/dL to proceed with screening activities.
During the screening period, mean hemoglobin <10 g/dL will be confirmed by [CONTACT_554449], 
(mean <10 g/dL), two up to eight weeks apart; or by [CONTACT_554425] (<10 g/dL) 
from the first assessment for patients receiving a pRBC transfusion after the first assessment.
Transfusion administered based on hemoglobin during the Screening period
If, in the Investigator’s judgment, a participant conditions meets the conditions for transfusion 
as per local requirements, the participant must be transfused with packed-RBC.
If a participant receives a packed-RBC transfusion following the first assessment carried out 
for the Screening visit (central laboratory), he/she will be eligible without an additional 
hemoglobin assessment by [CONTACT_2237].
[COMPANY_001] Confidential Page 57 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Transfusion administration will be recorded on a dedicated CRF page, where signs and 
symptoms are also reported as needed. If a participant refused to receive a blood transfusion, 
the CRF page must be completed indicating that the packed-RBC was not administered per 
participant’s decision.
8.1.3 Absolute Reticulocytes Count during Screening
The absolute reticulocytes count will be measured at Screening to determine eligibility with 
regards to exclusion criterion # 6. Due to the kinetics of maturation of reticulocytes into mature 
red blood cells and turnaround time from reticulocytes sample collection and analysis by [CONTACT_21921], local reticulocytes testing can be performed at the same time as the central testing 
during the Screening period. In the event that the absolute reticulocytes count as assessed by 
[CONTACT_554410] 
(absolute reticulocytes < 100x109/L) and only in this scenario, the results from the local lab 
testing can be used to determine participant’s eligibility. The results of the local laboratory 
values (including reference ranges) should be included in the eCRF to document eligibility.
8.2 Participant demographics/other baseline characteristics
Country-specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with CRF.
Participants demographic: full date (only if required and permitted) or year of birth or age, sex, 
race/predominant ethnicity (if permitted) and baseline characteristic data will be collected on 
all participants. Participant race/ethnicity are collected and analyzed to identify variations in 
safety or efficacy due to these factors as well as to assess the diversity of the study population 
as required by [CONTACT_6628].
Relevant medical history/current medical conditions will include: date for diagnosis of PNH 
(and age or disease duration will be derived up to the date of screening); vaccination history; 
MAVE history (dates and type); the packed-RBC transfusion received in the last 12 months 
prior to Screening; relevant medical history; smoking and alcohol history will also be collected.
Prior concomitant medications (including vitamins, herbal preparations, over the counter 
medications, and those medications highlighted in the entry criteria, as well as start date of 
anti-C5 treatment) and procedures (any therapeutic intervention including surgery, biopsies, 
or non-pharmacological therapy) taken prior to Screening will be recorded in the CRFs.
Prior anti-C5 antibody treatment regimen for PNH (eculizumab or ravulizumab), which must 
be stable for the [ADDRESS_728436] abnormality occurred prior to the informed consent signature.
8.3 Efficacy
Efficacy/pharmacodynamics assessments are specified below. Please refer to 
Table 8-1 and Table 8-2 for timepoints when these assessments are performed. Section 2 shows 
the correlation of the assessments with the objectives.
[COMPANY_001] Confidential Page 58 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
8.3.1 Hemoglobin, reticulocytes, LDH and other PNH-related laboratory 
parameters
Blood samples for hematology, clinical chemistry and  
 will be collected according to Table 8-1 for the randomized treatment period. 
The following laboratory parameters will be assessed: Hemoglobin , 
reticulocyte count and bilirubin (as markers for extravascular hemolysis), LDH (as a marker for 
intravascular hemolysis), 
During the treatment extension period, the assessment will be carried out as per Table 8-2.
Please refer to central laboratory manual regarding sample collection, numbering, processing 
and shipment.
8.3.[ADDRESS_728437] been established and will 
apply starting from Day 1 of the study.
Packed RBC transfusions will be administered to participants in the following cases:
Hemoglobin level ≤ 9 g/dL with signs /and or symptoms of sufficient severity to warrant a 
transfusion
Hemoglobin of ≤ 7 g/dL, regardless of presence of clinical signs and/or symptoms
The level of hemoglobin, the number and unit of transfusion administered as well as the signs 
and/or symptoms if applicable will be recorded in the CRFs. Symptoms typi[INVESTIGATOR_554388]’s need for transfusion are listed below:
Severe or worsening of fatigue
Severe or worsening dyspnea / shortness of breath
Palpi[INVESTIGATOR_332]/angina (or worsening symptoms)
Change in mental status (syncope, light-headedness, confusion, stroke, transient ischemic 
attack)
If a participant meets the transfusion criterion, the Investigator will determine the appropriate 
number of units of packed-RBC to be transfused.
The hemoglobin value on which the investigator will base the need for administering a packed-
RBC transfusion may be from the local laboratory due to the turnaround time for central lab 
results. However, the investigator must collect a separate sample for hemoglobin assessment by 
[CONTACT_554450] a sample for local lab analysis.
It is recommended that the transfusion is administered within 2-3 days of the assessment of the 
hemoglobin/event that triggered the requirement. In case the investigator or participant decides 
not to give or receive a transfusion despi[INVESTIGATOR_554389], the reason 
should be clearly documented in the CRF page.

[COMPANY_001] Confidential Page 59 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
During the treatment extension period, the need for administration of red blood cell transfusion 
will be monitored continuously until the end of study visit following the same criteria and 
guidance described above.
8.3.3 Breakthrough hemolysis
The occurrence of breakthrough hemolysis will be monitored continuously during the 
randomized treatment period. 
The criteria for clinical breakthrough is defined in Table 8-3 below if either one of the two 
clinical criteria is met, in presence of the laboratory evidence of intravascular hemolysis and 
should be reported in the 'Breakthrough hemolysis' CRF page in addition to the AE page. 
In contrast to clinical breakthrough as defined, the isolated laboratory evidence of increased 
intravascular hemolysis, without meaningful decrease in hemoglobin and without other clinical 
signs or symptoms of hemolysis (per Table 8-3), is defined as subclinical breakthrough 
hemolysis, and should not be reported in the 'Breakthrough hemolysis' CRF page.
Table 8-3 Breakthrough definition
Clinical criteria Laboratory criteria
Hemoglobin levels Signs or symptoms LDH level
Clinical 
breakthrough *Decrease equal to or more 
than 2 g/dL (compared to the 
latest assessment, or within 
15 days)Gross hemoglobinuria, 
painful crisis, dysphagia or 
any other significant clinical 
PNH-related signs & 
symptoms> 1.5-times ULN and 
increased as compared 
to the last 2 assessments
Subclinical 
breakthroughDecrease less than 2 g/dL 
(compared to the latest 
assessment, or within 15 
days)No clinical signs or 
symptoms, except moderate 
hemoglobinuria> 1.5-times ULN and 
increased as compared 
to the last 2 assessments
LDH: lactate dehydrogenase; ULN: Upper Limit of Normal;
*The breakthrough is defined clinical if either one of the two clinical criteria is demonstrated, in presence of 
laboratory evidence of intravascular hemolysis (LDH level)
During the treatment extension period, breakthrough hemolysis will be monitored continuously 
until the end of study visit following the same criteria and guidance described above.
The assessment could be based on the local laboratory results. However, the Investigator should 
also collect at the same time a sample for the central laboratory assessment of hemoglobin and 
LDH, whenever possible.
8.3.4 Patient Reported Outcomes (PRO) – FACIT-Fatigue 
The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its 
impact upon daily activities and function. It will be used to assess patient-reported fatigue. 
FACIT-Fatigue is one of many different FACIT scales part of a collection of Health-Related 
Quality of Life (HRQoL) questionnaires referred to as the FACIT Measurement System 
(Webster et al 2003, Yellen et al 1997). The use of the FACIT-F in PNH patients has been 
reported in several publications and is sensitive to changes in disease status, allowing 
demonstration of statistically significant and clinically meaningful results
[COMPANY_001] Confidential Page 61 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Amputation (non-traumatic; nondiabetic)
Cerebral arterial occlusion/cerebrovascular accident
Cerebral venous occlusion
Dermal thrombosis
Gangrene (non-traumatic; nondiabetic)
Hepatic/portal vein thrombosis (Budd‐Chiari syndrome)
Mesenteric/visceral arterial thrombosis or infarction
Mesenteric/visceral vein thrombosis or infarction
Myocardial infarction
Pulmonary embolus
Renal arterial thrombosis
Renal vein thrombosis
Thrombophlebitis / deep vein thrombosis
Transient ischemic attack
Unstable angina
Other, please specify
8.3.7 Appropriateness of efficacy assessments
The efficacy assessments including laboratory parameters hemoglobin (to determine the degree 
of anemia), LDH (as marker for intravascular hemolysis), reticulocytes, bilirubin and 
haptoglobin (as markers for extravascular hemolysis), and the need of red blood cell 
transfusions are important parameters for assessing treatment response in PNH. In fact, 
hemoglobin, the need of RBC transfusions are the determining parameters for classifying 
treatment response to complement inhibitor therapy with LDH and reticulocytes as ancillary 
parameters ( Risitano et al 2019). Breakthrough hemolysis is a phenomenon reported with 
eculizumab and also ravulizumab, therefore is part of the efficacy assessments in this study. 
Although the incidence of MAVEs is expected to be very low in the study population, it is 
important to assess it for a new complement inhibitor treatment. The majority of these efficacy 
assessments have been used in the eculizumab and ravulizumab registrations studies and will 
provide clinically relevant results for PNH. 
The FACIT-Fatigue Scale will measure various aspects of fatigue, one of the most debilitating 
and commonly reported symptom generally among PNH patients (Hill et al 2007), and among 
patients currently treated with eculizumab (Socie et al 2019). The use of the FACIT-F in PNH 
patients has been reported in several publications and is sensitive to changes in disease status, 
allowing demonstration of statistically significant and clinically meaningful results 
(Kulasekararaj et al 2019, Ueda et al 2018, Brodsky et al 2008). It has been well validated in 
general populations (Webster et al 2003; Yellen et al 1997) and content validity has been 
completed specifically in PNH patients (Weitz et al 2012 ).
[COMPANY_001] Confidential Page 62 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
8.4 Safety
Safety assessments are specified below with the assessment schedules (Table 8-1 and Table 8-2) 
detailing when each assessment is to be performed.
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e. pandemic, epi[INVESTIGATOR_6519], or in special circumstances that limits or 
prevents on-site study visits, and in case that an Off-site Research Nursing (ORN) visits are 
planned at that site (see Section 8.6), regular phone or virtual calls may occur (as per scheduled 
visits) for safety monitoring and discussion of the participant´s health status until the participant 
can again visit the site.
For details on AE collection and reporting, refer to AE Section 10.1.1 .
Table 8-4 Assessments and specifications
Assessment Specification
Physical 
examinationA complete physical examination will include the examination of general appearance, 
skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular, and neurological. If indicated, based on medical 
history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be 
performed.
Information for all physical examinations must be included in the source documentation 
at the study site. Clinically relevant findings that are present prior to signing informed 
consent must be recorded on the appropriate CRF that captures medical history. 
Significant findings made after signing informed consent which meet the definition of an 
Adverse Event must be recorded as an adverse event.
Vital signs Vital signs include BP and pulse measurements. After the participant has been sitting 
for five minutes, with back supported and both feet placed on the floor, systolic and 
diastolic blood pressure will be measured with an appropriately sized cuff. If the value 
reported is out of range, a repeat sitting measurements will be made at 5 - 10 minute 
later and the second measurement will be used/entered in the CRFs. 
Height and weight Height in centimeters (cm) is collected at Screening only; body weight (to the nearest 
0.1 kilogram (kg) assessed in indoor clothing, but without shoes) will be measured as 
specified in Table 8-1 and Table 8-2.
Body temperature The same route (temporal, tympanic, or axillary) and modality (temporal scanner, 
tympanic probe, thermometer) should be used for ongoing patient observations, as to 
allow for accurate temperature trend evaluation.
8.4.1 Laboratory evaluations
Unless specified in the table below, a central laboratory will be used for the analysis of the 
specimens collected. Details of collection, shipment, and reporting by [CONTACT_554451].
As per Section 4.6, if participants cannot visit the site for protocol specified safety lab 
assessments, an alternative lab (local) may be used as defined in Table 8-8.
Clinically notable laboratory findings are defined in Appendix 1.
Clinically significant abnormalities must be recorded as either medical history/current medical 
conditions or adverse events as appropriate.
[COMPANY_001] Confidential Page 64 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Single 12-lead ECGs are to be collected with ECG machines available at the site. The original 
ECGs and a certified copy on non-heat sensitive paper, appropriately signed, must be collected 
and archived at the study site.
For any ECGs with participant safety concerns (please refer to Appendix 1 for notable 
abnormalities), two additional ECGs must be performed to confirm the safety finding. If 
confirmed, a copy of the assessment should be sent to the [COMPANY_001] global team for expedited 
review. Clinically significant abnormalities must be recorded on the CRF as either medical 
history/current medical conditions or adverse events, as appropriate. Any identifier details must 
be redacted e.g. participant initials, date of birth.
8.4.[ADDRESS_728438] also be available as source documentation in the following 
cases:
1. Surgical bilateral oophorectomy without a hysterectomy
2. Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.
In the absence of the above medical documentation, FSH testing is required of any female 
participant regardless of reported reproductive/menopausal status at screening/baseline.
8.4.4 Coagulation panel/thrombosis
Blood samples will be analyzed at the Central laboratory for the following panel: D-dimer, 
fibrinogen, prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT).
8.4.5 Reproductive and thyroid hormones monitoring
The assessments indicated below will be carried out as per the Assessment schedules in 
Section 8 , and will be assessed in all participants.
[COMPANY_001] Confidential Page 70 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Participants, that the investigator identifies as suitable benefitting from off-site visits, must 
provide (a separate) consent in the optional Off-site Research Nursing Informed Consent. The 
participants are under no obligation to participate in off-site visits, as they can decide to continue 
with on-site visits at the study site.
The off-site location is not a site location where the investigator will conduct the trial and where 
source data will be maintained, but is for example the participant’s home or another safe 
location if assessed as suitable by [CONTACT_554452]-site Research Nurse (ORN) and ultimately decided 
by [CONTACT_737]. 
The off-site visit schedule will be determined in discussion between the participant, Investigator, 
and the Sponsor.
Conditions to enable off-site visits
Procedures conducted in an off-site location are carried out with the same level of scientific 
integrity as assessments conducted on-site. 
The following conditions must be met for off-site visits to occur:
Off-site visits may occur during the study duration for Week-2 and /or Week-6 visits or 
under exceptional circumstances and if agreed between investigator and Sponsor.
The participant must have completed at least Day 1 visit (i.e., confirmed eligibility and 
completed all visit assessments).
At least the first anti-C5 infusions must have occurred during the on-site period for 
participants on comparator arm (albeit performed as per local regulations and conditions)
If a participant has begun off-site visits and s/he suffers from either (1) a severe AE or an 
SAE (possibly related to study medication), and/or (2) any concurrent medical conditions 
which, in the opi[INVESTIGATOR_689], could cause unacceptable safety risks, then the 
participant must resume the on-site visits. The participant may resume the off-site visits 
when, based on the Investigator’s judgment, there are no further safety risks for the 
participant.
Off-site research nursing (ORN) personnel
The off-site visits will use a third-party vendor (wherever possible) centrally sourced by [CONTACT_554453], that can provide 
qualified research nurses who will perform study assessments under the oversight of the 
Investigator. Qualified ORN will be under delegation of the investigator. The investigator will 
retain accountability for participants’ oversight and all medical decisions (i.e. protocol specified 
medical procedures, AE/SAE assessment and reporting, changes in medication, etc.).
More details of the off-site research nursing process will be outlined in a separate manual 
provided to the sites participating in the off-site research nursing visits.
The ORN may collect and process Laboratory samples according to Table 8-8, which will then 
be shipped to the Central Laboratory. However, if results of these samples collected by [CONTACT_554454].
[COMPANY_001] Confidential Page 72 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Study treatment must be discontinued under the following circumstances:
Participant/guardian decision
Any situation in which study treatment might result in a significant safety risk to the 
participant 
If a female on LNP023 becomes pregnant during the study, it is recommended to discontinue 
treatment. However, after an individual benefit-risk assessment by [CONTACT_093], LNP023 
continuation may be considered in exceptional circumstances. Counseling should be provided 
to the participant on the appropriate treatment for PNH during pregnancy. The outcome of the 
discussion with the participant, reflecting benefit-risk considerations, should be documented in 
the participant's file.
If a female on anti-C5 therapy becomes pregnant during the study, the continuation of anti-C5 
therapy may be considered following an individual benefit-risk assessment by [CONTACT_093]. 
Guidance on pregnancy provided in the local label for the anti-C5 inhibitor should be followed. 
If treatment with LNP023 has to be discontinued immediately, i.e. because of a significant 
safety risk which warrants immediately stoppi[INVESTIGATOR_554379]023 treatment, it is recommended to 
promptly re-initiate anti-C5 antibody treatment, as judged by [CONTACT_093]. 
Close monitoring of participants for signs and symptoms of hemolysis should be performed 
upon LNP023 discontinuation. It is recommended to monitor at minimum for: increase in LDH, 
decrease in hemoglobin level and  increase in serum creatinine, thrombosis, and 
change in mental status. If serious hemolysis occurs, the Investigator should consider the 
following supportive treatments (and record them in the appropriate CRF pages):
Blood transfusion (packed RBCs),
Or exchange transfusion if the PNH RBCs are >50% of the total RBCs by [CONTACT_4133]
Corticosteroids
Anticoagulation
Any other supportive treatment or therapy as judged by [CONTACT_093]. 
A visit one week after permanent discontinuation of LNP023 should occur for the following 
assessments: LDH, creatinine, hemoglobin, coagulation/thrombosis markers (PT/INR, aPTT, 
D-dimer, and fibrinogen), , dipstick urinalysis, PNH signs and symptoms and 
all adverse events. All data collected will be entered in the appropriate CRF page.
If treatment with LNP023 has to be discontinued but it is not warranted to immediately 
discontinue LNP023 treatment, e.g., discontinuation due to participant/guardian decision, it is 
recommended to consider re-initiating the anti-C5 antibody treatment, as judged by [CONTACT_1275]. In addition, it should be considered to taper down LNP023 over a period of 14 
days, as follows:
3 capsules of 10 mg LNP023 taken in the evening (once daily) for 7 days
1 capsule of 10 mg LNP023 taken in the evening (once daily) for [ADDRESS_728439] LNP023 dose for the following assessments: LDH, 

[COMPANY_001] Confidential Page 73 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
creatinine, hemoglobin, coagulation/thrombosis markers (PT/INR, aPTT, D-dimer, and 
fibrinogen), , dipstick urinalysis, PNH signs and symptoms and all adverse 
events. All data collected will be entered in the appropriate CRF page.
Anti-C5 permanent discontinuation
For the permanent discontinuation of anti-C5, refer to the local label for recommended 
monitoring upon discontinuation.
Overall considerations
All dose changes must be recorded on the appropriate CRF.
Participants who discontinue study treatment or who decide they do not wish to participate in 
the study further should NOT be considered withdrawn from the study UNLESS they withdraw 
their consent (see 'Withdrawal of Informed Consent' section). 
Where possible, they should return for the assessments indicated in the Assessment 
Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g. 
telephone, e-mail, and letter) should be made to contact [CONTACT_2299]/pre-designated contact 
[CONTACT_49425]-up section. This contact [CONTACT_554455].
Participants who permanently discontinue study medication during the randomized treatment 
period, should complete the visits as scheduled up to Week 24. 
Participants who permanently discontinue study medication during the treatment extension 
period, should complete the visits as scheduled up to Week 48.
If discontinuation of study treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the participant’s premature discontinuation of study 
treatment and record this information.
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact [CONTACT_6635], or with a person pre-designated by [CONTACT_2299]. 
This telephone contact [CONTACT_6636].
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
New / concomitant treatments, including the need of RBC transfusions
Safety laboratory assessments
Adverse Events / Serious Adverse Events
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study treatment.
9.1.2 Withdrawal of informed consent
Participants may voluntarily withdraw consent to participate in the study for any reason at any 
time. Withdrawal of consent occurs only when a participant:

[COMPANY_001] Confidential Page 74 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Does not want to participate in the study anymore,
and
Does not want any further visits or assessments
and
Does not want any further study related contacts
In this situation, the investigator should make a reasonable effort (e.g. telephone, e-mail and 
letter) to understand the primary reason for the participant’s decision to withdraw his/her 
consent and record this information.
Where consent to the use of personal and coded data is not required, participant therefore cannot 
withdraw consent. They still retain the right to object to the further use of personal data.
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_30814]-up.
All efforts should be made to complete the assessments prior to study discontinuation. A final 
evaluation at the time of the participant’s study discontinuation should be made as detailed in 
the assessment table.
[COMPANY_001] will continue to retain and use all research results (data) that have already been 
collected for the study evaluation.
9.1.[ADDRESS_728440] show "due diligence" by 
[CONTACT_6638], e.g. dates of 
telephone calls, registered letters, etc. A participant should not be considered as lost to follow-
up until due diligence has been completed or until the end of the study.
9.1.4 Early study termination by [CONTACT_297230].
Reasons for early termination: 
Unexpected, significant, or unacceptable safety risk to participants enrolled in the study
Decision based on recommendations from applicable board(s) after review of safety and 
efficacy data
Discontinuation of study drug development
In taking the decision to terminate, [COMPANY_001] will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible (for an 
EOS visit) and treated as a prematurely withdrawn participant. The investigator may be 
informed of additional procedures to be followed in order to ensure that adequate consideration 
is given to the protection of the participant’s interests. The investigator or sponsor depending 
[COMPANY_001] Confidential Page 75 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
on local regulation will be responsible for informing IRBs/IECs of the early termination of the 
trial.
9.[ADDRESS_728441]-trial access 
(PTA) by [CONTACT_554430]-over extension program (REP) to allow participants’ access to 
LNP023 and to enable long-term safety monitoring. PTA will be provided until one of the 
following is met: participant no longer derives clinical benefit, investigator discontinues 
treatment, launch or reimbursement (where applicable), treatment fails to achieve registration 
in the trial participant’s country, or the clinical program is discontinued for any other reason.
10 Safety monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical 
investigation participant after providing written informed consent for participation in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility for managing the safety of each participant and 
identifying adverse events.
[COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105]-directive questioning of the participant 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_6643], laboratory 
test findings, or other assessments.
For participants who permanently discontinue LNP023 administration during the course of the 
study, or do not continue into the roll-over extension program (REP), AEs will be collected for 
[ADDRESS_728442] study visit (Day 336/EOS). 
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to 
Section 10.1.2):
[COMPANY_001] Confidential Page 76 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
1. The severity grade
mild: usually transient in nature and generally not interfering with normal activities
moderate: sufficiently discomforting to interfere with normal activities
severe: prevents normal activities
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression 
of underlying illness (i.e. progression of the study indication) the assessment of causality 
will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a 
lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they 
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of 
underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a 
single participant
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported
4. Whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5. Action taken regarding with study treatment.
All adverse events must be treated appropriately. Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug interrupted/withdrawn
6. Its outcome
Conditions that were already present at the time of informed consent should be recorded in 
medical history of the participant.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underlying signs and symptoms.
Adverse event monitoring should be continued at least until the last study visit.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or symptoms
they are considered clinically significant
they require therapy
[COMPANY_001] Confidential Page 77 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Clinically significant abnormal laboratory values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_6533]. Alert ranges for laboratory and other test abnormalities are included 
in Appendix 1.
[IP_ADDRESS] Adverse events of special interest
Adverse events of special interest (AESIs) are defined as events (serious or non-serious) which 
are of scientific and medical interest specific to [COMPANY_001]’s product or program, for which 
ongoing monitoring may be appropriate. Such events may require further investigation in order 
to characterize and understand them. Adverse events of special interest are defined on the basis 
of potential safety risks for the product, class effects and data from preclinical studies.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical conditions(s)] which meets any one of the 
following criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the ICH-E2D Guidelines).
results in persistent or significant disability/incapacity
constitutes a congenital anomaly/birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_6534]’s 
general condition
treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically significant, e.g. defined as an event that jeopardizes the participant or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be 
considered as “medically significant.” Examples of such events are intensive treatment in an 
[COMPANY_001] Confidential Page 78 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_6536] (please refer to the ICH-
E2D Guidelines).
All new malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
10.1.[ADDRESS_728443] be reported to 
[COMPANY_001] safety immediately, without undue delay, but under no circumstances later than within 
24 hours of obtaining knowledge of events (Note: If more stringent, local regulations regarding 
reporting timelines prevail). Detailed instructions regarding the submission process and 
requirements are to be found in the investigator folder provided to each site. Information about 
all SAE’s is collected and recorded on the (eSAE with paper back up) Serious Adverse Event 
Report Form; all applicable sections of the form must be completed in order to provide a 
clinically thorough report.
For participants NOT entering the roll-over extension program (REP), any SAEs experienced 
by [CONTACT_554456] [ADDRESS_728444] be reported as follow-up to the original epi[INVESTIGATOR_6538], without undue delay, but under no circumstances later than within 24 hours of the 
investigator receiving the follow-up information (Note: If more stringent, local regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or 
otherwise considered completely unrelated to a previously reported one must be reported 
separately as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study treatment, a CMO & PS Department 
associate may urgently require further information from the investigator for health authority 
reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
[COMPANY_001] Confidential Page 79 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Any SAEs experienced after the [ADDRESS_728445] study visit should only be reported 
to [COMPANY_001] Safety if the investigator suspects a causal relationship to study treatment, unless 
otherwise specified by [CONTACT_1769]/regulations.
10.1.[ADDRESS_728446] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy should be recorded and reported by [CONTACT_37288] (CMO&PS) on a Pharmacovigilance Pregnancy Form. Pregnancy 
follow-up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatment any pregnancy outcome. Any SAE experienced 
during pregnancy must also be reported. After consent is provided, the pregnancy be 
followed-up for one year after the estimated date of delivery.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by [CONTACT_3584].
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safety database irrespective of it being associated with an AE/SAE immediately, without undue 
delay, under no circumstances later than within 24 hours of Investigator’s awareness (Note: If 
more stringent, local regulations regarding reporting timelines prevail).
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in AE eCRF Complete SAE form
Unintentional study 
treatment errorYes Only if associated with an 
AEOnly if associated with an 
SAE
[COMPANY_001] Confidential Page 80 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Treatment error type Document in Dosing 
CRF (Yes/No)Document in AE eCRF Complete SAE form
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety Monitoring
10.2.1 Liver safety monitoring
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of 
an investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 16-1 in Appendix 2 for complete definitions of liver laboratory triggers.
Once a participant is exposed to study treatment, every liver event defined in Table 16-1 should 
be followed up by [CONTACT_6648], as summarized below. 
Additional details on actions required in case of liver events are also outlined in 
Table 16-1. Repeat liver chemistry tests (i.e. ALT etc.) to confirm elevation.
These liver chemistry repeats will be performed using the central laboratory. If results will not 
be available from the central laboratory, then the repeats can also be performed at a local 
laboratory to monitor the safety of the participant. If a liver event is subsequently reported, any 
local liver chemistry tests previously conducted that are associated with this event should have 
results recorded on the appropriate CRF.
If the initial elevation is confirmed, close observation of the participant will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the Discontinuation of study treatment 
section), if appropriate
Hospi[INVESTIGATOR_6539]
Causality assessment of the liver event
Thorough follow-up of the liver event should include:
Obtaining a more detailed history of symptoms and prior or concurrent diseases.
Obtaining a history of concomitant drug use (including nonprescription medications 
and herbal and dietary supplement preparations), exposure to environmental chemical 
agents, alcohol use, recreational drug use, and special diets.
Exclusion of underlying liver disease
These investigations can include based on investigator’s discretion:
Imaging such as abdominal US, CT or MRI, as appropriate
Considering gastroenterology or hepatology consultations.
All follow-up information and procedures performed must be recorded as appropriate in the 
CRF.
[COMPANY_001] Confidential Page 81 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
10.2.2 Data Monitoring Committee
This study will include a Data Monitoring Committee (DMC) which will function 
independently of all other individuals associated with the conduct of this clinical trial, including 
the site investigators participating in the study. The DMC will assess at defined intervals the 
progress of a clinical trial, safety data, and critical efficacy variables of value for assessing 
benefit/risk to study participants, and recommend to the sponsor whether to continue, modify, 
or terminate a trial.
Specific details regarding composition, responsibilities, data monitoring, meeting frequency, 
and documentation of DMC reports, minutes, and recommendations will be described in a 
separate charter that is established between the sponsor and the DMC. Analyses reviewed by 
[CONTACT_554457].
10.2.3 Steering Committee
The Steering Committee (SC) will be established comprising investigators participating in the 
trial, i.e. not being members of the DMC and [COMPANY_001] representatives from the Clinical Trial 
Team.
The SC will ensure transparent management of the study according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publications of study results including authorship rules. The 
details of the role of the steering committee will be defined in the steering committee charter.
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to [ADDRESS_728447] been trained. Automatic validation programs 
check for data discrepancies in the eCRFs, allow modification and/or verification of the entered 
data by [CONTACT_6649].
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. 
The Investigator must certify that the data entered are complete and accurate.
After final database lock, the investigator will receive copi[INVESTIGATOR_157052].
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification.
[COMPANY_001] Confidential Page 82 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
11.2 Database management and quality control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly to queries and to make any necessary changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical 
Therapeutic Chemical classification system. Medical history/current medical conditions and 
adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
terminology.
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed to the participant and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a vendor, who will also manage the database. The data will be sent 
electronically to [COMPANY_001] (or a designated CRO) at specific timelines.
Once all the necessary actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be released and made 
available for data analysis of the randomized treatment period. Before this it will be made 
available in a restricted area to be accessed by [CONTACT_554458]. Any changes to the database after that time can only be made 
after written agreement by [CONTACT_188660].
11.3 Site monitoring
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eCRFs) with the 
investigators and their staff. During the study, [COMPANY_001] employs several methods of ensuring 
protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will 
visit the site to check the completeness of participant records, the accuracy of data capture / data 
entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, 
and to ensure that study treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 
visits.
Continuous remote monitoring of each site’s data may be performed by [CONTACT_5343]. Additionally, 
a central analytics organization may analyze data & identify risks & trends for site operational 
parameters, and provide reports to [COMPANY_001] clinical teams to assist with trial oversight.
The investigator must maintain source documents for each participant in the study, consisting 
of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
participant's file. The investigator must also keep the original informed consent form signed by 
[CONTACT_2299] (a signed copy is given to the participant).
[COMPANY_001] Confidential Page 83 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary variables. Additional 
checks of the consistency of the source data with the CRFs are performed according to the 
study-specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.
12 Data analysis and statistical methods
A clinical study report (CSR) will be produced for submission at the time the last participant 
has completed the randomized treatment period. This section describes the methods associated 
to this report.
An additional CSR will be produced when the last participant has completed the last visit in the 
treatment extension period, when the final study database has been locked.
Any data analysis carried out independently by [CONTACT_85689].
12.1 Analysis sets
The Randomized Analysis Set (RAS) consists of all randomized participants. This data set will 
not be used for any analyses, and solely for providing complete information on how participants 
were randomized. 
The Full Analysis Set (FAS) comprises all participant to whom study treatment has been 
assigned by [CONTACT_17628], and will exclude participants to whom a randomization number has 
been assigned in error (mis-randomized participants). According to the intent to treat principle, 
participants will be analyzed according to the treatment they have been assigned to, taking into 
account the strata in which they were included during the randomization procedure. This will 
be the data set used for analysis of all efficacy endpoints.
The Safety Set includes all participants who received at least one dose of study treatment. 
Participants will be analyzed according to the study treatment they received, where treatment 
received is defined as the randomized/assigned treatment if the participant took at least one dose 
of that treatment or the first treatment received if the randomized/assigned treatment was never 
received.
The analysis set including the complete follow up of participants up to the completion of the 
treatment extension period will be defined in the corresponding SAP.
[COMPANY_001] Confidential Page 84 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
12.[ADDRESS_728448] deviation, median, 25th and 75th percentiles, minimum, 
and maximum will be presented.
The duration of exposure (in days) to LNP023 and anti-C5 antibody treatment as well as the 
dose intensity and the relative dose intensity will be summarized by [CONTACT_554459].
In addition, the duration of exposure (in days) reflecting the compared treatment strategies: 
LNP023 + transfusions and anti-C5 antibody treatment + transfusions, will be summarized to 
describe exposure corresponding to treatment policy.
Concomitant medications and significant non-drug therapi[INVESTIGATOR_554390] (ATC) 
classification system, by [CONTACT_1570].
12.4 Analysis of the primary endpoint(s)/estimand(s)
In the study protocol, 'absence of transfusions' or 'not requiring transfusions' refers to not 
receiving transfusions and not meeting the criteria for administration of transfusions as per  
Section 8.3.2 .
12.4.1 Definition of primary endpoint(s)/estimand(s)
Here we define the two primary endpoints corresponding to the primary estimands. The primary 
endpoint defines the response as sustained increase in hemoglobin and a participant as a 
responder if:
The change from baseline in hemoglobin is ≥ 2 g/dL on three out of four measurements 
taken at the visits occurring in last six weeks (from Day 126 to Day 168) of the 
randomized treatment period, and
The participant has not met the criteria (i.e. not received and not met the criteria for 
administration as per Section 8.3.2) for administration of RBC transfusions between Day 
14 and Day 168.
The baseline hemoglobin will be the mean of the two measurements taken during 
screening that confirm the hemoglobin entry criterion in participants who do not receive a 
transfusion between the first and second confirmatory measurement. In participants who 
[COMPANY_001] Confidential Page 85 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
receive a transfusion after the first confirmatory measurement, the baseline will be the first 
measurement.
The primary endpoint defines response as the achievement of sustained hemoglobin levels and 
a participant will be a responder if:
The hemoglobin levels are ≥ 12 g/dL on three out of four measurements taken at the visits 
occurring in last six weeks (from Day 126 to Day 168) of the randomized treatment 
period, and 
The participant has not required (i.e. not received and not met the criteria for 
administration as per Section 8.3.2) any RBC transfusions between Day 14 and Day 168. 
12.4.2 Statistical model, hypothesis, and method of analysis
The overall study Type I error is one-sided 0.025. Superiority of LNP023 in achieving a larger 
proportion of participants who reach a sustained hemoglobin response compared to anti-C5 
antibody treatment will be tested by [CONTACT_554460]023 ( ) to the probability of response on anti-C5 antibody treatment ( ) for 
both endpoints as:
The test of hypothesis will be implemented by [CONTACT_6486] a conditional logistic regression model, 
which conditions on a sufficient statistic for each stratum within which participants were 
randomized, and includes as covariates both sex, age (indicator of age ≥ 45 years), and an 
indicator variable of baseline hemoglobin above 9 g/dL, the same for each of the two endpoints.
The multiplicity adjustment to be applied for the test of two primary endpoints as well as to the 
secondary endpoints for which the study wise Type I error is controlled, is described graphically 
in Figure 12.1.
To adjust for multiplicity of the simultaneous test of two primary endpoints, we will apply a 
weighted permutation test with equal weights to each of the two endpoints. In order to account 
for the correlation between the two primary endpoints due to the overlap in participants who 
would be positive for both criteria as well as for the small sample size, the reference distribution 
of the p-values will be derived using 50,000 permuted realizations of the treatment labels within 
each randomization stratum and obtaining the p-values of each of the two endpoints for each 
realization of permuted treatment labels. The observed p-values from each fit with the actual 
treatment labels will be compared with the 1.25th percentiles of the 50,000 resulting p-values 
from fits with permuted treatment labels for each of the two endpoints (Westfall and 
Troendle 2008, Westfall and Wolfinger 1997, Westfall et al1993).

[COMPANY_001] Confidential Page 86 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
The summary measure provided will be the odds ratio derived as the coefficient for treatment 
effect from the conditional logistic regression. This corresponds to an overall estimate where 
the intercept parameter is dropped from the likelihood by [CONTACT_554461]-responders. The estimated odds ratios and their confidence intervals will be provided for 
each of the two endpoints as well as the corresponding p-values.
The secondary endpoint hypotheses are described in Section 12.5. Figure 12-1 describes an 
abbreviated version of the alpha propagation rules following principles described in 
Bretz et al. (2009, 2011) which can be summarized as follows:
1. Hypotheses H1 and H2 are tested using the permutation test described above. The 
available ½ study alpha may be distributed between the two as shown in the figure by 
[CONTACT_511056] 10% from a successfully rejected hypothesis.
2. Secondary endpoints H3 and hypotheses H41, H42, and H43 denoted by [CONTACT_554462] H4i if a 
primary endpoint hypothesis is rejected, are tested by a weighted Simes procedure with 
50% of weight available for secondary endpoints (45%) given to H3 and the other 50% of 
the corresponding weight (45%) given equally to hypotheses in H4i.
3. Secondary endpoints in H5i: H51, H52, and H53 are tested after successful rejection of 
hypotheses in H1, H2, H3, and H4i.
The alpha weights as shown in the graph are only schematic and should not be interpreted as 
compatible with the principles of the intended graphical procedure. Full details including 
complete alpha propagation rules not available in the abbreviated version here are provided in 
Appendix 3.
Figure 12-1 Graphical display of multiple testing procedure 

[COMPANY_001] Confidential Page 87 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
12.4.[ADDRESS_728449] on hemoglobin levels will also take into 
account the treatment participants were on at the time of withdrawal from study.
For participants withdrawing from study follow up after discontinuation of LNP023, the 
model implemented will recover a return to pre-treatment levels of Hb. This would be 
implemented by [CONTACT_554463] (anti-C5 antibody treatment) whose on 
treatment response would be considered similar to the pre-treatment levels in participants 
in the LNP023 arm.
For anti-C5 randomized participants withdrawing from study, missing data will be imputed 
by [CONTACT_554464]-C5 antibody treatment arm.
For participants with intermittent missing data during study follow up where reasons for 
missingness are assumed to be unrelated to response or compliance status, their missing 
data will be handled with a missing at random approach and imputed consequently. 
The full specification will be provided in the SAP. 
12.4.5 Sensitivity analyses for primary endpoint/estimand
The sensitivity of the primary estimands with respect to the treatment of missing data described 
above will be evaluated using a tippi[INVESTIGATOR_18275]. An additional sensitivity analysis of the 
use of a conditional logistic regression model including covariates will be carried out using a 
Cochran-Mantel Haenszel test instead. This assessment will be detailed in the SAP.
12.4.6 Supplementary analysis
A supplementary analysis for each of the two primary endpoints considering the use of rescue 
therapy (as defined in Section 6.2.3) as treatment failure will be performed. The supplementary 
estimand will have the same population, treatment of interest, summary measure as the primary 
estimand in Section 2.1. The intercurrent events for the supplementary estimand will be the 
following: 
[COMPANY_001] Confidential Page 88 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Transfusions will be considered treatment failures whereas discontinuations of study 
medication for any reason will be handled with treatment policy strategy. Use of rescue 
medication (to treat serious complications such as thrombosis or for significant breakthrough 
hemolysis) will be defined as an intercurrent event and handled using a composite strategy: 
patients receiving rescue medication will be considered as treatment failure.
12.4.[ADDRESS_728450] the marginal probability of response for all participants in the 
study if they had received LNP023 or anti-C5 antibody treatment. The confidence intervals for 
the difference as well as for the ratio of proportions will be derived by [CONTACT_554465]. Cases 
of non-convergence due to sparsity will be handled within a penalized likelihood (Firth) 
approach.
The comparisons of proportions described above will be further displayed for subgroup 
categories defined by [CONTACT_554466], previous anti-C5 antibody treatment, 
length of time since diagnosis, age categories, sex, and baseline hemoglobin. 
Potential impact of a new wave of COVID-[ADDRESS_728451] 
of COVID-19 infections will be specified in detail in an amendment to the SAP developed in 
the event of renewed COVID-19 infection waves. Decisions on handling of possible increases 
in background risks impacting study endpoints will also take into consideration relevant 
epi[INVESTIGATOR_554391]-19 infections.
12.5 Analysis of secondary endpoints/estimands
The secondary estimands described below will be tested after successful rejection of the null 
hypothesis associated with the primary estimands following the pre-defined weighting scheme 
applied to the tests of secondary endpoints and the alpha propagation rules synthesized in the 
graphical scheme. In addition to the analysis of the secondary estimands, we also show the 
hypothesis identifier used in Figure 12-1.
For all estimands defined in this section, we consider the same intercurrent events as for the 
primary estimands, except in the case when the intercurrent event itself is considered an 
endpoint. For RBC transfusions, the treatment given to it will depend on the endpoint and this 
is described below. In the case of discontinuation of study medication, breakthrough hemolysis 
[COMPANY_001] Confidential Page 89 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
events, and MAVEs expected to be reflected in the endpoint the analysis will apply treatment 
policy, for all endpoints.
H3: Transfusion avoidance will be evaluated comparing the proportion of participants not 
receiving (i.e. not receiving and not met the criteria for administration as per Section 8.3.2) any 
RBC transfusion during Day 14 and Day 168, similarly to the comparison applied to the primary 
estimand by [CONTACT_554467] 
(including in both cases the randomization strata and covariates).
H41: Comparison of change from baseline in hemoglobin levels under the hypothetical 
situation in which participants would not have received RBC transfusions on any of the 
treatments. This will be accomplished by [CONTACT_554468] a normal 
distribution whose mean is restricted to a range consistent with not having received an RBC 
transfusion and the within visit covariance matrix will borrow from the observed within 
participant covariance matrix, to replace hemoglobin values following a transfusion. The model 
for the comparison between treatments is a repeated measures model with an unstructured 
covariance structure, with stratification factors and including main effect of treatment, visit and 
baseline, and the interactions between visits and treatment and visits and baseline levels. 
Additional covariates will be age (as binary indicator) and sex. The treatment contrasts will be 
computed as the comparison of treatments corresponding to the average measured in the last 6 
weeks of randomized treatment (that is the visits occurring between Day 126 and Day 168). 
H42: The endpoint consists of changes from baseline in scores of fatigue using the FACIT-
Fatigue questionnaire where baseline is defined as the mean of levels obtained pre-
randomization (Screening visit) and the Day [ADDRESS_728452] scores collected at all visits. The 
comparison between treatments will be an average of treatment estimates derived for visits 
occurring between Day 126 and Day 168. Main effects will be stratification factors and baseline 
covariates and interaction terms will be similar as those used to compare changes in hemoglobin.
H43: The comparison of the change from baseline in reticulocyte counts will be derived from 
a longitudinal repeated measures model including data collected throughout the study and 
where baseline is defined as the value on Day 1. In this model, stratification factors, baseline 
covariates as well as interaction terms will be the same as for changes in hemoglobin. The 
comparison between treatments will use the average of model derived estimates for each 
treatment obtained at visits occurring between Day 126 and Day 168.
H51: The treatment effect on percent change from baseline in LDH will be assessed using a 
longitudinal repeated measures model of log transformed ratio to baseline based on all 
observations collected during follow-up. The model is similar to the model described for all 
continuous endpoints. Treatment comparisons will be derived based on the average of the log 
transformed ratio in each treatment estimated between Day 126 and Day 168. 
H52: The comparison of rates of breakthrough hemolysis will be carried out using a negative 
binomial model. Stratification factors and covariates will be included similarly as for the other 
endpoints.
[COMPANY_001] Confidential Page 90 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
H53: The comparison of rates of Major Adverse Vascular Events (MAVE) will be carried 
out using a negative binomial model. Due to the expected low frequency of occurrences, no 
covariates are planned to be included.
Supportive analyses
To complement the secondary estimand analysis of average changes in hemoglobin under a 
hypothetical strategy, the analysis comparing average changes in hemoglobin will be repeated 
using a treatment policy approach, to obtain the comparison of the combination of LNP + 
transfusions as needed to anti-C5 antibody treatment + transfusions as needed.
In addition the comparison of changes from baseline in hemoglobin will also be carried out 
quantifying the effect of the treatments compared that is mediated by [CONTACT_554469].
Missing data for secondary endpoints
Missing data during study follow up will be imputed following the same principles as for the 
primary estimands/endpoints. This treatment involves pattern mixture models for withdrawal 
from study follow up using the reason for withdrawal modeled to capture the impact on 
hematological response or the need for RBC transfusions. In case of intermittent missing data, 
when reasons for missingness were consistent with the assumption of missing at random, the 
missing observations will be imputed under this assumption. 
The imputation approach used for hemoglobin data that were missing following a transfusion, 
in the case of intermittent missing data will be the same as for the hypothetical estimand. In the 
case of definitive withdrawal of study follow up following a transfusion only hemoglobin levels 
at visits during 30 days following the transfusion would be imputed under the this approach, 
while the hemoglobin and other measurements involved in the secondary estimands will be 
imputed using a pattern mixture model according to principles described in Section 12.4.4.
In all comparisons based on a longitudinal model, missing data will be imputed multiple times. 
The imputed datasets will be used in the estimation of the longitudinal model. Where both 
intercurrent events (as for the hypothetical estimand comparing hemoglobin levels) and missing 
data are imputed or where only missing data are imputed, the model comparisons will be derived 
using Rubin’s combination rules.
Treatment Extension period
The efficacy endpoints of interest will still be the same as during the randomized treatment 
period, namely, proportions achieving response, hemoglobin, scores of FACIT-Fatigue, 
reticulocyte counts, LDH, as well as occurrences of breakthrough hemolysis and MAVEs 
throughout the 48 weeks of follow up. These analyses will be fully detailed in the extension 
SAP.
12.5.1 Safety endpoints
The analysis set used for all safety analyses will be the safety set (SAF). All tables will be 
presented by [CONTACT_1570]. The complete details of all safety summaries will be provided in 
[COMPANY_001] Confidential Page 91 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
the SAP. The following mentions safety outcomes of interest and provides a non-exhaustive 
description of principles to be followed in the preparation of outputs.
Safety summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In particular, summary tables for adverse events (AEs) will summarize 
only on-treatment events, with a start date during the on-treatment period (treatment-emergent 
AEs). In addition, a separate summary of death events including on treatment and post treatment 
deaths will be provided if appropriate.
The on-treatment period lasts from the date of first administration of study treatment to [ADDRESS_728453] actual administration of LNP023 which covers slightly more than 5 
times the estimated half-life of LNP023.
Adverse events
All information obtained on adverse events will be displayed by [CONTACT_131373].
The number (and percentage) of participants with treatment emergent adverse events (events 
started after the first dose of study medication or events present prior to start of randomized 
treatment but increased in severity based on preferred term) will be summarized in the following 
ways:
by [CONTACT_3148], primary system organ class and preferred term.
by [CONTACT_3148], primary system organ class, preferred term and maximum severity.
Separate summaries will be provided for study medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation, and adverse events 
leading to discontinuation of study medication, and for LNP023 tapering if this is followed prior 
to complete study dose discontinuation.
The number (and proportion) of participants with adverse events of special interest/related to 
identified and potential risks will be summarized by [CONTACT_3148].
A participant with multiple adverse events within a primary system organ class is only counted 
once towards the total of the primary system organ class.
Vital signs
Summary statistics will be provided by [CONTACT_10659]/time. Summary occurrence of 
abnormalities may be provided by [CONTACT_554470].
12-lead ECG
PR, QRS, QT, QTcF, and RR intervals will be obtained from 12-lead ECGs for each participant 
during the study. ECG data will be read and interpreted locally. 
Categorical Analysis of QT/QTc interval data based on the number of participants meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from baseline 
will be presented. In addition, a listing of these participants will be produced (by [CONTACT_6490]).
[COMPANY_001] Confidential Page 95 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
assumption that the proportions are 35% on LNP023 treatment and 5% on anti-C5 antibody 
treatment and it is 89.1% for a significance level of 0.0125. The sample size/power calculations 
were carried out using the package exact 2x2 by [CONTACT_554471], Hunsberger, Nason, and Gabriel and R 
version 3.4.3. Power for the simultaneous test cannot be exactly derived but a minimum power 
corresponding to assuming a Bonferroni adjustment is approximately 95% for the above 
described marginal power assumptions.
12.8.2 Secondary endpoint(s)
Nominal power for prioritized secondary endpoints corresponding to hypotheses H3, H41, H42, 
and H43 is estimated to be between 85% and 90% at full study alpha (one-sided 0.025), without 
considering the adjustment for multiple testing derived from the procedure used. The three 
hypotheses tested as H51, H52 and H53 are estimated to have lower power, hence the alpha 
allocated is very small, leading to a test at full study alpha only after rejection of all primary 
endpoint hypotheses and secondary endpoint hypotheses H3 and H4i.
13 Ethical considerations and administrative procedures
13.1 Regulatory and ethical compliance
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (IRB/IEC) for the trial protocol, 
written informed consent form, consent form updates, participant recruitment procedures 
(e.g., advertisements) and any other written information to be provided to participants. Prior to 
study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to conduct the study in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records 
to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents 
of [COMPANY_001], IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical 
site is requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately 
that this request has been made.
13.[ADDRESS_728454]. In addition, after study completion and finalization of the study report 
the results of this trial will be submitted for publication and posted in a publicly accessible 
database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required 
Health Authority websites (e.g. Clinicaltrials.gov, EudraCT etc.).
[COMPANY_001] Confidential Page 96 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
For details on the [COMPANY_001] publication policy including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings.
13.[ADDRESS_728455] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes.
[ADDRESS_728456] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and Health Authorities, where required, it cannot be implemented.
14.[ADDRESS_728457] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only amendments that are required for participant safety may be implemented immediately 
provided the health authorities are subsequently notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any participant included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study site should be informed according to 
local regulations.
[COMPANY_001] Confidential Page 97 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
[ADDRESS_728458].
Aaronson NK, Ahmedzai S, et al (1993) The European Organization for Research and 
Treatment of Cancer QLQ-C30: A Quality-of-Life instrument for use in international clinical 
trials in oncology. J Natl Cancer Inst; 85:365-76.
Anthony L, Ervin C, Lapuerta P et al (2017) Understanding the Patient Experience with 
Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of 
Telotristat Ethyl. Clin Therapeut; 39(11):2158-68.
Borowitz MJ, Craig FE, DiGuseppe JA, et al (2010) Guidelines for the diagnosis and 
monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by [CONTACT_4133]. 
Cytometry B Clin Cytom; 78B:211-30.
Bretz F,Maurer W, Brannath W, et al (2009) A graphical approach to sequentially rejective 
multiple test procedures. Stat Med; 28: 586-604.
Bretz F, Maurer W, and Hommel, G (2011) Test and power considerations for multiple 
endpoint analyses using sequentially rejective graphical procedures. Stat Med 30: 1489-501.
Brodsky RA, Young NS, Antonioli E, et al (2008) Multicenter phase 3 study of the 
complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal 
hemoglobinuria. Blood; 4:1840-7.
Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood; 124:2804–11.
Debureaux P-E, Cacace F, Silva BGP, et al (2019) Hematological Response to Eculizumab in 
Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify 
Unmet Clinical Needs and Future Clinical Goals. Blood; 134 (1 Supplement):3517.
DeZern AE, Dorr D, Brodsky RA, et al (2013) Predictors of hemoglobin response to 
eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol; 90: 16–24.
EuroQol Research Foundation. EQ-5D-5L User Guide (2019) Available from: 
//euroqol.org/publications/user-guides.
Fayers P, Bottomley A (2002) Quality of life research within the EORTC-the EORTC QLQ-
C30. Eur J Cancer; 38: 125S-33S. 
Hill A, Richards SJ, Hillmen P (2007) Recent developments in the understanding and 
management of paroxysmal nocturnal haemoglobinuria. Br J Haematol; 137:181-92.
Hill A, Rother RP, Arnold L, et al (2010) Eculizumab prevents intravascular hemolysis in 
patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular 
hemolysis occurring through C3 opsonization. Haematologica; 95:567-73.
Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria. 
Blood;121: 4985-96.
Hillmen P, Young NS, Schubert J, et al (2006) The complement inhibitor eculizumab in 
paroxysmal nocturnal hemoglobinuria. N Eng J Med; 355:1233-43.
[COMPANY_001] Confidential Page 98 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Hillmen P, Muus P, Duhrsen U, et al (2007) Effect of the complement inhibitor eculizumab 
on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood; 
110:4123-8.
Konar M, Granoff DM (2017) Eculizumab treatment and impaired opsonophagocytic killing 
of meningococci by [CONTACT_554472]. Blood; 130:891-9.
Kulasekararaj AG, Hill A, Rottinghaus ST, et al (2019) Ravulizumab (ALXN1210) vs 
eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood; 
133:540-9.
Lee JW, Sicre de Fontbrune F, Lee LWL, et al (2019) Ravulizumab (ALXN1210) vs 
eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood; 
133:530-9.
McKinley C, Richards SJ, Munir T, et al (2017) Extravascular Hemolysis Due to C3-Loading 
in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. ASH 
meeting abstract. Blood; 130([ADDRESS_728459].):3471.
Nishimura J, Yamamoto M, Hayashi S, et al (2014) Genetic variants in C5 and poor response 
to eculizumab. N Engl J Med; 370:632-9.
FDA 2020 Patient Focused Drug Development: Collecting comprehensive and representative 
input (PFDD). Guidance for industry, food and drug administration staff, and other 
stakeholders. 
Rabin R, and de Charro F (2001) EQ-SD: a measure of health status from the EuroQol Group. 
Ann Med; 33:337-3.
Risitano AM, Notaro R, Marando L, et al (2009) Complement fraction 3 binding on 
erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria 
patients treated by [CONTACT_151305]. Blood; 113:4094-100.
Risitano AM (2012) Paroxysmal nocturnal hemoglobinuria and other complement-mediated 
hematological disorders. Immunology; 217:1080-7.
Risitano AM, Marotta S, Ricci P, et al (2019) Anti-complement treatment for Paroxysmal 
Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper 
from the SAAWP of the EBMT. Front Immunol; 10:1157.
Staunton H, Willgoss T, Nelsen L et al (2019) An overview of using qualitative techniques to 
explore and define estimates of clinically important change on clinical outcome assessments. J 
Pat Rep Outcomes; 3(16): 1-10.
Socie G, Tosi MP, Marantz JL, et al (2019) Eculizumab in paroxysmal nocturnal 
haemoglobinuria and atypi[INVESTIGATOR_554392]: 10-year pharmacovigilance 
analysis. Br J Haematol; 185:297–310.
Ueda Y, Obara N, Yonemura Y, et al (2018) Effects of eculizumab treatment on quality of life 
in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol; 107:656-65.
[COMPANY_001] Confidential Page 99 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Webster K, Cella D, and Yost K (2003) The functional assessment of chronic illness therapy 
(FACIT) measurement system: properties, applications, and interpretation. Health Qual Life 
Outcomes; 16:1-79.
Weitz I, Meyers G, Lamy T, et al (2012) Cross-sectional validation study of patient-reported 
outcomes in patients with paroxysmal nocturnal haemaglobinuria. Intern Med J; 43: 298-307.
Westfall, PH and Troendle, JF (2008) Multiple testing with minimal assumptions. Biom J, 
50:5:745-55.
Westfall, PH and Wolfinger RD (1997) Multiple tests with discrete distributions. Am Stat; 
51(1):3-8.
Westfall PH, Young SS, Lin Y (1993) Resampling-based multiple testing: Examples and 
methods for p-value adjustment. [LOCATION_001]: Wiley Interscience.
Yellen SB, Cella DF, Webster K, et al (1997) Measuring fatigue and other anemia-related 
symptoms with functional assessment of cancer therapy (FACT) measurement system. J Pain 
Symmptom Manage; 13:33-74.
[COMPANY_001] Confidential Page 100 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
16 Appendices
16.1 Appendix 1: Clinically notable laboratory values 
Renal alert values
Once a participant is exposed to study treatment, the following two categories of abnormal renal 
laboratory alert values should be assessed during the study period:
Serum creatinine increase ≥ 25% compared to baseline during normal hydration status
New onset dipstick proteinuria ≥ 3+ 
Abnormal renal event findings must be confirmed after ≥24 hours but ≤ [ADDRESS_728460] 
assessment. Causes and possible interventions should be considered.
ECG alert values
Resting heart rate sinus rhythm < 30 or a HR decrease ≥ 25% or
HR > 130 [bpm]
QRS >120 or increase >25% compared to predose baseline [msec]
QTcF >500 or increase >60 compared to predose baseline [msec]
Ventricular tachycardia
New complete heart block (Grade III AV block) or Mobitz II AV block
For any ECGs with participant safety concerns, two additional ECGs must be performed to 
confirm the safety finding.
[COMPANY_001] Confidential Page 101 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
16.2 Appendix 2: Liver event and laboratory trigger definitions & 
follow-up requirements 
Table 16-1  Definitions of Triggers, Actions and Follow-up requirements for liver 
events
Criteria Actions required Follow-up monitoring
Potential Hy’s 
Law case
(Elevated 
ALT/AST > 3 × 
ULN and TBL > 
2 × ULN but 
without notable 
increase in ALP 
to > 2 × ULN – or 
[ADDRESS_728461] in the 
presence of bone 
pathology)Discontinue the study treatment immediately 
(if possibly related to study treatment)
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality (investigate alternative 
etiologies)a
Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory value) in the appropriate eCRFALT, AST, TBL, Alb, PT/INR, 
ALP, GGT, CK and GLDH 
(frequency at Investigator 
discretion)
Monitor for symptomsb
Report outcomec
ALT 
> 8 × ULN Interrupt the study treatment (if possibly 
related to study treatment)
Hospi[INVESTIGATOR_18553]
Establish causality (investigate alternative 
etiologies)a
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFALT, AST, TBL, Alb, PT/INR, 
ALP and GGT (frequency at 
Investigator discretion)
Monitor for symptomsb
Report outcomec
> 3 × ULN and 
INR > 1.5 (in the 
absence of 
anticoagulation)
If elevated at 
baseline:
> 2 x baseline
or > 300 U/L 
(whichever 
occurs ﬁrst)Interrupt the study treatment (if possibly 
related to study treatment)
Hospi[INVESTIGATOR_18553]
Establish causality (investigate alternative 
etiologies)a
Study drug can be restarted only if alternative 
etiology is identified and liver enzymes return 
to baseline
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFALT, AST, TBL, Alb, PT/INR, 
ALP and GGT until resolution 
(frequency at Investigator 
discretion)
> 5 to ≤ 8 × ULN
If elevated at 
baseline:
> 3 x baseline
or > 300 U/L 
(whichever 
occurs ﬁrst)Repeat LFT within 48 hours
If elevation persists, continue follow-up 
monitoring
If elevation persists for more than 2 weeks, 
discontinue the study drug
Establish causality (investigate alternative 
etiologies)a
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFALT, AST, TBL, Alb, PT/INR, 
ALP and GGT until resolution 
(frequency at Investigator 
discretion)
> 3 × ULN to ≤ 5 
× ULN Interrupt the study treatment (if possibly 
related to study treatment)ALT, AST, TBL, Alb, PT/INR, 
ALP and GGT until resolution 
[COMPANY_001] Confidential Page 102 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Criteria Actions required Follow-up monitoring
(accompanied by 
[CONTACT_23805])b
If elevated at 
baseline:
> 2 x baseline
or > 300 U/L 
(whichever 
occurs ﬁrst)Hospi[INVESTIGATOR_18553]
Establish causality (investigate alternative 
etiologies)a
Study drug can be restarted only if alternative 
etiology is identified and liver enzymes return 
to baseline
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRF(frequency at Investigator 
discretion)
Monitor for symptomsb
Report outcomec
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)b
If elevated at 
baseline:
> 2 x baseline
or > 300 U/L 
(whichever 
occurs ﬁrst)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the participantInvestigator discretion
Monitor LFT within 1 to 4 weeks
ALP (isolated)
> 2 × ULN (in the 
absence of 
known bone 
pathology)
>[ADDRESS_728462] in the 
presence of bone 
pathologyRepeat LFT within 48 hours
If elevation persists, establish causality 
(investigate alternative etiologies)a
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Liver events
Jaundice Interrupt the study treatment (if possibly 
related to study treatment)
Hospi[INVESTIGATOR_6548]
Establish causality (investigate alternative 
etiologies)a
Study drug can be restarted only if alternative 
etiology is identified and liver enzymes return 
to baseline
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFALT, AST, TBL, Alb, PT/INR, 
ALP and GGT until resolution 
(frequency at Investigator 
discretion)
Monitor symptomsb
Report outcomec
Any AE 
potentially 
indicative of a 
liver toxicitydConsider study treatment interruption or 
discontinuation
Hospi[INVESTIGATOR_6549]
Establish causality (investigate alternative 
etiologies)a
Record the AE and contributing factors (e.g. 
con meds, med hx, lab) in the appropriate 
eCRFInvestigator discretion
a Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history 
of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver 
disease
[COMPANY_001] Confidential Page 103 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
Criteria Actions required Follow-up monitoring
bSevere fatigue, malaise (general), abdominal pain (right upper quadrant), nausea, vomiting or rash with 
eosinophilia
cResolved = return to Day 1 values; Condition unchanged = stable values at three subsequent monitoring visits 
at least 2 weeks apart; Condition deteriorated = values worsen or liver transplantation; and Fatal.
dThese events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related 
conditions; the non-infectious hepatitis; the benign, malignant and unspecified liver neoplasms. 
TBL: total bilirubin; ULN: upper limit of normal
[COMPANY_001] Confidential Page 104 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
16.3 Appendix 3: Full description of graphical procedure used for 
testing of primary and secondary endpoints
Hypotheses H51, H52 and H53 are tested only after successful rejection of H1, 
H2, H3, H41, H42, and H43 
1. The primary endpoint hypotheses are both tested at ½ alpha (0.025/2=0.0125) each, with 
the p-value level corresponding to rejection derived using the permutation method described 
above. If only one of the 2 hypotheses, H1 (increase in hemoglobin ≥ 2 g/dL from baseline) 
and H2 (reaching a fixed threshold ≥ 12 g/dL) is rejected using the 1.25% percentile of the 
permuted p-values, the rejected hypothesis may pass 10% of the local alpha to the other 
hypothesis. The increased alpha fraction available is equivalent to using the 1.375% 
percentile of the permuted p-values to be compared with the observed p-value for the 
hypothesis that failed to be rejected using the 1.25% percentile.
2. If a primary endpoint hypothesis is rejected, its local alpha is the passed on to the set of four 
secondary endpoint hypotheses H3, H41, H42, and H43. The test of these hypotheses is a 
weighted Simes closed testing procedure, and the alpha propagation rules reflect the weights 
given: ½ of the local alpha available for the secondary endpoint hypotheses (45%) is passed 
on to H3, while the other 45% is propagated using equal weights to the 3 hypotheses denoted 
as H41, H42, and H43. If rejected H3 passes the available local alpha equally to all 3 

[COMPANY_001] Confidential Page 105 of 105
Amended Clinical Trial Protocol 
Version 02 (Clean)  Protocol No. CLNP023C12302
hypotheses H41, H42, and H43. The alpha propagation between the [ADDRESS_728463] been 
rejected, their local alpha will be propagated back to the primary endpoint hypotheses 
(represented by [CONTACT_941] 2 epsilon edges from H43 to H1 and to H2).
3. If all hypotheses (H1, H2, H3, H4i) are rejected, the three hypotheses in H5i will be tested 
using a weighted Simes’ closed testing procedure at full study alpha, where weights of 
0.475 are given to each of H51 and H52, and 0.05 to H53. If one of H51 or H52 is 
rejected, its local alpha up to 90% will be passed to the other hypothesis at the same 
weight level, and 10% to H53. The weights for alpha propagation from H53 are described 
in the graph.
Approval Signatures
Compound: LNP023
Document Title: CLNP023C12302-protocol v02
Document Name: 02.01.0201 Protocol - v02
Document Version: 2.0
Username [CONTACT_442118] 2021-11-26
15:11:24 (UTC)
Content Approval 2021-11-26
16:05:22 (UTC)
Content Approval 2021-11-26
16:31:03 (UTC)
Document electronically signed
